0001493152-22-012931.txt : 20220512 0001493152-22-012931.hdr.sgml : 20220512 20220512082928 ACCESSION NUMBER: 0001493152-22-012931 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 52 CONFORMED PERIOD OF REPORT: 20220331 FILED AS OF DATE: 20220512 DATE AS OF CHANGE: 20220512 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Indaptus Therapeutics, Inc. CENTRAL INDEX KEY: 0001857044 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 863158720 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-40652 FILM NUMBER: 22915830 BUSINESS ADDRESS: STREET 1: 3 COLUMBUS CIRCLE STREET 2: 15TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: 347-480-9760 MAIL ADDRESS: STREET 1: 3 COLUMBUS CIRCLE STREET 2: 15TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: Intec Parent Inc. DATE OF NAME CHANGE: 20210414 10-Q 1 form10q.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2022

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

FOR THE TRANSITION PERIOD FROM TO

Commission File Number 001-40652

Indaptus Therapeutics, Inc.

(Exact name of Registrant as specified in its Charter)

Delaware

86-3158720

(State or other jurisdiction

of incorporation or organization)

(I.R.S. Employer

Identification No.)

3 Columbus Circle

15th Floor

New York

10019

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: +(347) 480 9760

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common stock, par value $0.01 per share		INDP		Nasdaq Capital Market

Indicate by check mark whether the Registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. YES ☒ NO ☐

Indicate by check mark whether the Registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the Registrant was required to submit and post such files). YES ☒ NO ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging growth company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the Registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). YES ☐ NO ☒

The number of shares of Registrant’s ordinary shares outstanding as of May 10, 2022: 8,258,597.

TABLE OF CONTENTS

		Page

PART I — FINANCIAL INFORMATION

Item 1.	Condensed Consolidated Financial Statements (Unaudited)
	Condensed Consolidated Balance Sheets	F-1
	Condensed Consolidated Statements of Operations	F-2
	Condensed Consolidated Statements of Stockholders’ Equity	F-3
	Condensed Consolidated Statements of Cash Flows	F-4
	Notes to Condensed Consolidated Financial Statements	F-5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	3
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	9
Item 4.	Controls and Procedures	10

PART II — OTHER INFORMATION

Item 1.	Legal Proceedings	11
Item 1A.	Risk Factors	11
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	11
Item 3.	Defaults upon Senior Securities	11
Item 4.	Mine Safety Disclosures	11
Item 5.	Other Information	11
Item 6.	Exhibits	11

PART I. FINANCIAL INFORMATION

Item 1.

Financial Statements

INDAPTUS THERAPEUTICS, INC.

Unaudited Condensed Consolidated Balance Sheets

	March 31, 2022			December 31, 2021
Assets
Current assets:
Cash and cash equivalents	$	33,216,311		$	39,132,165
Marketable securities		2,961,460			-
Assets held for sale		-			148,400
Prepaid expenses and other current assets		741,945			1,106,653

Total current assets		36,919,716			40,387,218

Non-current assets:
Property and equipment, net		3,266			3,800
Right-of-use asset		147,102			169,088
Other assets		16,477			16,477

Total non-current assets		166,845			189,365

Total assets	$	37,086,561		$	40,576,583

Liabilities and stockholders’ equity
Current liabilities:
Accounts payable and other current liabilities	$	3,582,472		$	4,507,676
Operating lease liability, current portion		97,185			96,465

Total current liabilities		3,679,657			4,604,141

Non-current liabilities:
Operating lease liability, net of current portion		50,516			72,862

Total non-current liabilities		50,516			72,862

Total liabilities		3,730,173			4,677,003

Commitments and contingent liabilities (Note 8)		-

Stockholders’ equity:
Common stock: $0.01 par value, 200,000,000 shares authorized as of March 31, 2022 and December 31, 2021; 8,258,597 shares issued and outstanding as of March 31, 2022 and December 31, 2021		82,586			82,586
Additional paid in capital		52,319,064			51,487,881
Accumulated deficit		(19,036,041	)		(15,670,887	)
Accumulated other comprehensive loss		(9,221	)		-

Total stockholders’ equity		33,356,388			35,899,580

Total liabilities and stockholders’ equity	$	37,086,561		$	40,576,583

See accompanying notes to the unaudited condensed consolidated financial statements

F-1

INDAPTUS THERAPEUTICS, INC.

Unaudited Condensed Consolidated Statements of Operations

	2022			2021
	Three Months Ended March 31,
	2022			2021
Operating expenses:
Research and development	$	1,297,098		$	489,721
General and administrative		2,104,975			124,254

Total operating expenses		3,402,073			613,975

Loss from operations		(3,402,073	)		(613,975	)

Other income, net		36,919			1,554

Net loss	$	(3,365,154	)	$	(612,421	)

Net loss available to common stockholders per share of common stock, basic and diluted	$	(0.41	)	$	(0.31	)

Weighted average number of shares used in calculating net loss per share, basic and diluted		8,258,597			1,944,672
Net loss	$	(3,365,154	)	$	(612,421	)
Other comprehensive loss:
Unrealized loss on available-for-sale securities		(9,221	)		-
Comprehensive loss	$	(3,374,375	)	$	(612,421)

See accompanying notes to the unaudited condensed consolidated financial statements

F-2

INDAPTUS THERAPEUTICS, INC.

Unaudited Condensed Consolidated Statements of Stockholders’ Equity (Deficit)

	Shares		Amount		Shares		Amount		capital		deficit			Loss			Total
	Series Seed Preferred				Common stock				Additional paid in		Accumulated			Accumulated Other Comprehensive
	Shares		Amount		Shares		Amount		capital		deficit			Loss			Total

Balance, January 1, 2021		835,928	$	8,359		1,944,672	$	19,447	$	7,693,994	$	(7,959,501	)	$	-		$	(237,701	)
Stock-based compensation		-		-		-		-		20,445		-			-			20,445
Net loss		-		-		-		-		-		(612,421	)					(612,421	)
Balance, March 31, 2021		835,928		8,359		1,944,672		19,447		7,714,439		(8,571,922	)		-			(829,677	)

Balance, January 1, 2022		-		-		8,258,597	$	82,586	$	51,487,881	$	(15,670,887	)		-		$	35,899,580

Stock-based compensation		-		-		-		-		831,183		-			-			831,183
Other comprehensive loss															(9,221	)		(9,221	)
Net loss		-		-		-		-		-		(3,365,154	)		-			(3,365,154	)

Balance, March 31, 2022		-	$	-		8,258,597	$	82,586	$	52,319,064	$	(19,036,041	)	$	(9,221	)	$	33,356,388

See accompanying notes to the unaudited condensed consolidated financial statements

F-3

INDAPTUS THERAPEUTICS, INC.

Unaudited Condensed Consolidated Statements of Cash Flows

	2022			2021
	For the three months ended
	March 31,
	2022			2021
Cash flows from operating activities:
Net loss	$	(3,365,154	)	$	(612,421	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation		534			213
Stock-based compensation		831,183			20,445
Realized gain on assets held for sale		(24,155	)		-
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		364,708			(109,883	)
Accounts payable and other current liabilities		(925,204	)		481,050
Deferred transaction costs		-			(604,988	)
Operating lease right-of-use asset and liability, net		360			-
Net cash used in operating activities		(3,117,728	)		(825,584	)

Cash flows from investing activities:
Proceeds received for assets held for sale		172,555			-
Purchase of marketable securities		(2,970,681	)		-
Net cash used in investing activities		(2,798,126	)		-

Cash flows from financing activities:
Proceeds from SAFEs, net		-			3,675,000
Net cash provided by financing activities		-			3,675,000

Net (decrease) increase in cash and cash equivalents		(5,915,854	)		2,849,416

Cash and cash equivalents at beginning of period		39,132,165			1,637,499

Cash and cash equivalents at end of period	$	33,216,311		$	4,486,915

Supplemental cash flow disclosures
Cash paid for income taxes	$	-		$	800
Cash received for interest earned on deposits	$	1,318		$	506

See accompanying notes to the unaudited condensed consolidated financial statements

F-4

INDAPTUS THERAPEUTICS, INC.

Notes to the unaudited condensed consolidated financial statements

NOTE 1: GENERAL

Indaptus Therapeutics, Inc. and its wholly-owned subsidiaries, Decoy Biosystems, Inc. and Intec Pharma Ltd., collectively (the “Company”), is a biotechnology company dedicated to enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas, which are responsible for more than 90% of all cancer deaths. The Company is developing a novel, multi-targeted product that activates both innate and adaptive anti-tumor and anti-viral immune responses.

Indaptus Therapeutics, Inc. (“Indaptus”), formerly “Intec Parent Inc.”, was established and incorporated in Delaware on February 24, 2021, as a private Delaware corporation and wholly-owned subsidiary of Intec Pharma Ltd., (“Intec Israel”), a former publicly traded company.

On August 3, 2021, Indaptus completed its merger with Decoy Biosystems, Inc., (“Decoy”), following the satisfaction or waiver of the conditions set forth in the Agreement and Plan of Merger (the “Merger Agreement”), dated as of March 15, 2021 among Indaptus, Decoy, Intec Israel, Domestication Merger Sub Ltd., an Israeli company and a wholly-owned subsidiary of Indaptus (“Domestication Merger Sub”), and Dillon Merger Subsidiary Inc., a Delaware corporation and wholly-owned subsidiary of Indaptus (“the Merger Sub”), pursuant to which Merger Sub merged with and into Decoy, with Decoy surviving as a wholly-owned subsidiary of Indaptus (the “Merger”) and the business conducted by Decoy became the business conducted by Indaptus. Previously, on July 26, 2021, Intec Israel implemented a 1-for-4 reverse share split of its outstanding ordinary shares, options and warrants and proportionate adjustments were made to its exercise prices. In addition, on July 27, 2021, Intec Israel, Indaptus and the Domestication Merger Sub, completed the domestication merger pursuant to the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated April 27, 2021, whereby Domestication Merger Sub merged with and into Intec Israel, with Intec Israel being the surviving entity and a wholly-owned subsidiary of Indaptus.

Also, in connection with the Merger, Indaptus changed its name from “Intec Parent, Inc.” to “Indaptus Therapeutics, Inc.”. Following completion of the Merger, shares of Indaptus common stock commenced trading at market open on August 4, 2021, on the Nasdaq Capital Market under the name “Indaptus Therapeutics, Inc.” and under the symbol “INDP”.

In connection with the Merger, on July 23, 2021, Indaptus entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional investor, pursuant to which Indaptus agreed to sell and issue, in a private placement (the “Private Placement”), pre-funded warrants and warrants for total net proceeds of approximately $27.3 million, after deducting the placement agent’s fees and other estimated offering expenses payable by Indaptus in the amount of approximately $2.7 million. In September 2021, the pre-funded warrant was fully exercised. Each warrant is exercisable at an exercise price of $11.00 per share and has a term of five and one-half years from the date of issuance. In addition, in connection with the Private Placement, Indaptus issued to the placement agent a warrant to purchase 136,364 shares of Indaptus’ common stock at an exercise price of $13.75.

Risks and uncertainties

The Company is subject to a number of risks similar to those of other companies of similar size in its industry, including, but not limited to, the need for successful development of products, the need for additional capital (or financing) to fund operating losses (see below), competition from substitute products and services from larger companies, protection of proprietary technology, patent litigation, and dependence on key individuals.

F-5

The COVID-19 pandemic has resulted in significant financial market volatility and uncertainty in the past year. The COVID-19 pandemic is affecting the United States and global economies and may affect the Company’s operations and those of third parties on which the Company relies, including by causing disruptions in the supply of its product candidates and the conduct of future clinical trials. For example, the pandemic has caused our good manufacturing practice (GMP) process to take longer than expected. In addition, the COVID-19 pandemic may affect the operations of the FDA and other health authorities, which could result in delays of reviews and approvals, including with respect to the Company’s product candidates. Additionally, while the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce the Company’s ability to access capital, which could negatively impact its short-term and long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. While it is unknown how long these conditions will last and what the complete financial effect will be to the Company, capital raise efforts and additional development of the Company’s technologies may be negatively affected.

Going concern and management’s plans

The Company has incurred net losses and utilized cash in operations since inception, has an accumulated deficit as of March 31, 2022, of $19.0 million, and expects to incur future additional losses as clinical testing and commercialization of the Company’s product candidates will require significant additional financing. The Company believes it has adequate cash to fund its operations for at least one year after the date of issuance of these condensed consolidated financial statements.

Management plans to raise additional capital through equity and/or debt financings, or other capital sources, including potential collaborations, licenses, and other similar arrangements. However, these plans are not entirely within its control and cannot be assessed as being probable of occurring. The Company’s ability to raise additional capital may be adversely impacted by potential worsening of global economic conditions and the recent disruptions to, and volatility in, financial markets in the United States and worldwide resulting from the developing conflict between Russia and Ukraine and the ongoing COVID-19 pandemic. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce, or eliminate its research and development programs or other operations. If any of these events occur, the Company’s ability to achieve the development and commercialization goals would be adversely affected.

These condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.

NOTE 2: SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and S-X Article 10 for interim financial statements. Accordingly, they do not contain all information and notes required by US GAAP for annual financial statements. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company’s consolidated financial position as of March 31, 2022, the consolidated results of operations, changes in stockholders’ equity and cash flows for the three-month periods ended March 31, 2022, and 2021.

These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual financial statements for the year ended December 31, 2021, as filed in the 10-K on March 21, 2022. The condensed consolidated balance sheet data as of December 31, 2021, included in these unaudited condensed consolidated financial statements was derived from the audited financial statements for the year ended December 31, 2021, but does not include all disclosures required by US GAAP for annual financial statements.

The results for the three-month period ended March 31, 2022, are not necessarily indicative of the results expected for the year ending December 31, 2022.

Principles of consolidation

The consolidated financial statements include the accounts of Indaptus and its subsidiaries. Intercompany balances and transactions have been eliminated upon consolidation.

Use of estimates

The preparation of the unaudited condensed consolidated financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods. The most significant estimates relate to the determination of the fair value of stock-based compensation and the determination of period-end obligations to certain contract research organizations. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. These estimates are based on information available as of the date of the consolidated financial statements; therefore, actual results could differ from those estimates.

F-6

Loss per share

Loss per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of common stock outstanding during the period. Diluted loss per share is based upon the weighted average number of common stock and of common stock equivalents outstanding when dilutive. Common stock equivalents include outstanding stock options and warrants which are included under the treasury stock method when dilutive.

The following number of stock options and warrants were excluded from the calculation of diluted loss per share because their effect would have been anti-dilutive for the periods presented (share data):

SCHEDULE OF ANTI-DILUTIVE SECURITIES

	2022		2021
	For the three months ended March 31,
	2022		2021
Outstanding stock options		1,580,623		206,079
Warrants		3,090,787		-
Anti-dilutive securities		3,090,787		-

Cash and cash equivalents

The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of March 31, 2022 and December 31, 2021, cash and cash equivalents consist primarily of checking and money market deposits. The Company’s cash balances exceed those that are federally insured; however, the Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. To date, the Company has not recognized any losses caused by uninsured balances.

Marketable securities

The Company’s investment in marketable securities included U.S. treasury bonds that are classified as available-for-sale securities pursuant to Accounting Standards Codification (“ASC”) 320 “Investments — Debt Securities”. These investments are recorded at fair value with unrealized gains and losses recorded in Accumulated Other Comprehensive Income (Loss), or AOCI, as a separate component of stockholders’ equity.

Property and equipment

Property and equipment assets are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The Company uses an estimated useful life of three years for employee-related computers and other office equipment and five years for furniture. Leasehold improvements are amortized over the shorter of the lease-term or the estimated useful life of the related asset.

Patents

The Company expenses patent costs, including related legal costs, as incurred and records such costs within general and administrative expense in the accompanying consolidated statements of operations.

F-7

Research and development expenses

Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including clinical trials and professional services. All costs associated with research and developments are expensed as incurred.

The Company accrues for expenses resulting from obligations under agreements with contract research organizations (“CROs”), contract manufacturing organizations (“CMOs”), and other outside service providers for which payment flows do not match the periods over which services or materials are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements with CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. In the event advance payments are made to a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset, which will be amortized or expensed as the contracted services are performed.

Income taxes

Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded for deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will not be realized in the foreseeable future. As of March 31, 2022 and December 31, 2021, the Company has recorded a full valuation allowance against its deferred tax assets.

The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expenses.

Stock-based compensation

The Company measures and records the expense related to stock-based payment awards based on the fair value of those awards as determined using the Black-Scholes-Merton (“Black-Scholes”) option pricing model as of the date of grant. The Company recognizes stock-based compensation expense over the requisite service period of the individual grant, generally equal to the vesting period, on a straight-line basis.

The Black-Scholes model requires the use of highly subjective and complex assumptions, which determine the fair value of stock-based awards, including the option’s expected term and the price volatility of the underlying stock. The Company estimates the fair value of options granted by using the Black-Scholes model with the following assumptions:

Expected Volatility—The Company estimated volatility for option grants by evaluating the historical volatility of a peer group of companies for the period immediately preceding the option grant for a term that is approximately equal to the options’ expected term.

F-8

Expected Term—The expected term of the Company’s options represents the period that the stock-based awards are expected to be outstanding. The expected term was estimated using the simplified method for employee stock options since the Company does not have adequate historical exercise data to estimate the expected term.

Risk-Free Interest Rate—The risk-free interest rate is based on the implied yield currently available on US Treasury zero-coupon issues with a term that is equal to the options’ expected term at the grant date.

Dividend Yield—The Company has not declared or paid dividends to date and does not anticipate declaring dividends. As such, the dividend yield has been estimated to be zero.

The Company has elected to recognize forfeitures as they occur.

Fair value measurements

Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company follows the established framework for measuring fair value and providing disclosures about fair value measurements.

The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:

Level 1:	Quoted prices in active markets for identical assets or liabilities.

Level 2:	Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.

Level 3:	Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

ASC 820, Fair Value Measurement, requires all entities to disclose the fair value of financial instruments, both assets and liabilities, for which it is practicable to estimate fair value, and defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of March 31, 2022 and December 31, 2021, the recorded values of cash and cash equivalents, marketable securities, assets held for sale, prepaid expenses, and accounts payable and other current liabilities approximate their fair values due to the short-term nature of these items.

F-9

NOTE 3: MARKETABLE SECURITIES

The Company’s investment in marketable securities included U.S. treasury bonds with maturities of less than one year. These investments are classified as available-for-sale and are recorded at fair value with unrealized gains and losses recorded in AOCI. These investments are categorized as Level 2.

As of March 31, 2022, the amount of the marketable securities is $2,961,460. As of December 31, 2021, the Company had no marketable securities.

The unrealized losses for the three-month period ended March 31, 2022 amounted to $9,221.

NOTE 4: PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets are comprised of the following:

	March 31,		December 31,
	2022		2021
Prepaid insurance	$	543,986	$	945,023
Prepaid research and development		78,353		127,643
Other receivables		-		21,056
Other prepaid expenses		119,606		12,931
Total prepaid expenses and other current assets	$	741,945	$	1,106,653

NOTE 5: ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES

Accounts payable and other current liabilities are comprised of the following:

	March 31,		December 31,
	2022		2021
Accounts payable	$	2,834,683	$	2,637,806
Accrued employee costs		276,285		1,371,136
Accrued professional fees		71,186		139,871
Accrued research and development		175,978		135,751
Accrued board fees		116,000		125,333
Delaware franchise taxes payable		50,000		-
Other accrued expenses		58,340		97,778
Total accounts payable and other current liabilities	$	3,582,472	$	4,507,676

NOTE 6: STOCK-BASED COMPENSATION

In June 2021, the Intec Israel shareholders voted to approve the Indaptus 2021 Stock Incentive Plan, an equity incentive plan for grants to employees, officers, consultants, directors and other service providers, (the “2021 Plan”), that became effective upon the closing of the Merger. The 2021 Plan provides for up to 1,864,963 shares of the Company’s common stock.

The 2021 Plan provides for the grant of non-qualified stock options, incentive stock options, restricted stock awards, restricted stock units, unrestricted stock awards, stock appreciation rights and other forms of stock-based compensation. The 2021 Plan permits the Company’s board to change the type, terms and conditions of awards as circumstances may change. This flexibility to adjust the type of compensation to be granted is particularly important given current economic and world events.

F-10

On January 26, 2022, Indaptus’ board of directors approved grant of options to purchase 289,200 shares of common stock to executives. The options are exercisable at $4.90 per share, vest over three years, and expire ten years after grant.

On February 1, 2022, Indaptus’ board of directors approved a grant of options to purchase 90,000 shares of common stock to a new employee. The options are exercisable at $4.97 per share, vest over three years, and expire ten years after grant.

On February 25, 2022, Indaptus’ board of directors approved a grant of options to purchase 60,000 shares of common stock to an executive. The options are exercisable at $4.18 per share, vest over three years, and expire ten years after grant.

A summary of the stock option activity during the three months ended March 31, 2022, is presented in the table below:

SCHEDULE OF SHARE BASED COMPENSATION

				Weighted average
	Number of options			Exercise price		Remaining contractual life (in years)		Intrinsic value
Outstanding as of January 1, 2022		1,174,600		$	17.10		9.1	$	241,103
Granted		439,200		$	4.82		9.8	$	-
Exercised		-		$	-		-	$	-
Forfeited and cancelled		(33,237	)	$	11.46		9.3	$	-
Outstanding as of March 31, 2022		1,580,623		$	13.80		9.2	$	96,870
Exercisable as of March 31, 2022		127,749		$	81.20		6.3	$	96,870
Vested and expected to vest March 31, 2022		1,580,623		$	13.80		9.2	$	96,870

The Company recognized stock-based compensation expense of $831,183 and $20,445 during the three months ended March 31, 2022 and 2021, respectively. The following table summarizes the total stock-based compensation expense included in the condensed consolidated statements of operations for the periods presented:

	2022		2021
	For the three months ended March 31,
	2022		2021
Research and development	$	170,163	$	8,189
General and administrative		661,020		12,256
Total stock-based compensation expense	$	831,183	$	20,445

As of March 31, 2022, total compensation cost not yet recognized related to unvested stock options was approximately $6.7 million, which is expected to be recognized over a weighted-average period of 2.3 years.

The Company estimates the fair value of stock options on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires estimates of highly subjective assumptions, which affect the fair value of each stock option. The weighted average inputs used to measure the value of the options granted during the three months ended March 31, 2022 are presented in the table below. The weighted average fair value of stock options issued during the three months ended March 31, 2022 was $3.89 per share.

	2022
Stock price	$	4.82
Exercise price	$	4.82
Expected term (in years)		5.9
Volatility		105.5	%
Risk free rate		1.7	%
Dividend yield		0.0	%

F-11

The following table presents the exercise price of outstanding stock options as of March 31, 2022:

Exercise price	Options outstanding
$0.01 - $8.00		539,925
$8.01 - $16.00		1,006,000
$16.00 or higher		34,698
Total		1,580,623

NOTE 7: CAPITALIZATION

	a.	As of March 31, 2022 and December 31, 2021, the Company had 200,000,000 shares of common stock authorized and 8,258,597 shares of common stock issued and outstanding.

	b.	As of March 31, 2022 and December 31, 2021, there were warrants outstanding to purchase an aggregate of 3,090,787 shares of common stock of Indaptus. As of March 31, 2022, these warrants are exercisable at a weighted average price of $12.50 and their weighted average remaining contractual term is 4.7 years.

NOTE 8: COMMITMENTS AND CONTINGENCIES

Litigation

As of the date of issuance of these consolidated financial statements there were no pending legal proceedings against the Company that are expected to have a material adverse effect on cash flows, financial condition or results of operations. From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically, the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation.

Leases

On October 1, 2021, the Company entered into a noncancelable two-year operating lease agreement for approximately 2,000 square feet of office space in San Diego, California. The base rent is $7,999 per month with an increase of 3% after the first anniversary of the lease term commencement, which was November 1, 2021. The lease liability is measured at a discount rate of 7%.

Future minimum annual lease payments under the Company’s noncancelable operating lease as of March 31, 2022 are as follows:

SUMMARY OF MINIMUM LEASE PAYMENTS

2		2022
2022	$	72,469
2023		82,387
Total minimum lease payments		154,856
Less: amount representing interest		(7,155	)
Present value of operating lease liability		147,701
Less: current portion		(97,185	)
Operating lease liability, net of current portion	$	50,516

The Company recognized rent expense of $26,542 and $6,365 during the three months ended March 31, 2022 and 2021, respectively. Total cash payments for the operating lease totaled $26,182 and $6,365 during the three months ended March 31, 2022 and 2021, respectively.

NOTE 9: SUBSEQUENT EVENTS

The Company evaluated subsequent events from March 31, 2022, the date of these consolidated financial statements, through May 12, 2022, which represents the date the consolidated financial statements were issued, for events requiring recognition or disclosure in the condensed consolidated financial statements for the three-month period ended March 31, 2022. The Company concluded that no events have occurred that would require recognition or disclosure in the consolidated financial statements.

F-12

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

Unless the context indicates otherwise, in this Quarterly Report on Form 10-Q, the terms “Indaptus,” “Company,” “we,” “us” and “our” refer to Indaptus Therapeutics, Inc. (formerly Intec Parent, Inc. the successor of Intec Pharma Ltd. following the domestication merger) and, where appropriate, its consolidated subsidiaries following the domestication merger and the reverse merger described below. References to “Intec Israel” refer to Intec Pharma Ltd., the predecessor of Indaptus prior to the domestication merger described below, and references to “Decoy” refer to Decoy Biosystems, Inc., the entity acquired by Indaptus in connection with the reverse merger described below.

The following discussion and analysis provides information that we believe to be relevant to an assessment and understanding of our results of operations and financial condition for the periods described. This discussion should be read together with our condensed consolidated financial statements and the notes to the financial statements, which are included in this Quarterly Report on Form 10-Q. This information should also be read in conjunction with the information contained in our Annual Report on Form 10-K for the year ended December 31, 2021, filed with the Securities and Exchange Commission on March 21, 2022, including the consolidated annual financial statements as of December 31, 2021 and their accompanying notes included therein. We have prepared our condensed consolidated interim financial statements in accordance with U.S. GAAP and Article 10 of SEC Regulation S-X.

This Quarterly Report on Form 10-Q of Indaptus Therapeutics, Inc. contains forward-looking statements about our expectations, beliefs and intentions. Forward-looking statements can be identified by the use of forward-looking words such as “believe”, “expect”, “intend”, “plan”, “may”, “should”, “could”, “might”, “seek”, “target”, “will”, “project”, “forecast”, “continue” or “anticipate” or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. These forward-looking statements are based on assumptions and assessments made in light of management’s experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements in Quarterly Report on Form 10-Q are made as of the date of this Quarterly Report on Form 10-Q, and we undertake no duty to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. Many factors could cause our actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: our plans to develop and potentially commercialize our technology, the timing and cost of our planned investigational new drug application and any clinical trials, the completion and receiving favorable results in any clinical trials, our ability to obtain and maintain regulatory approval of any product candidate, our ability to protect and maintain our intellectual property and licensing arrangements, our ability to develop, manufacture and commercialize our product candidates, the risk of product liability claims, the availability of reimbursement, the influence of extensive and costly government regulation, expenses capital requirements and the need for additional financing following the recently completed merger. More detailed information about the risks and uncertainties affecting us is contained under the heading “Risk Factors” included in our most recent Annual Report on Form 10-K filed with the SEC on March 21, 2022, and in other filings that we have made and may make with the Securities and Exchange Commission in the future.

Overview

We are a pre-clinical biotechnology company developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. We have evolved from more than a century of immunotherapy advances. Our approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Our patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, with reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. This approach has led to broad anti-tumor and anti-viral activity, including safe, durable anti-tumor response synergy with each of five different classes of existing agents, including checkpoint therapy, targeted antibody therapy and low-dose chemotherapy in pre-clinical models. Tumor eradication by our technology has demonstrated activation of both innate and adaptive immunological memory and, importantly, does not require provision of or targeting a tumor antigen in pre-clinical models. We have carried out successful GMP manufacturing of our lead clinical candidate, Decoy20, and completed other IND-enabling studies.

Unlike many competitor products, our technology does not depend on targeting with or to a specific antigen, providing broad applicability across multiple indications. Our product candidates are designed to have a much shorter half-life and produce less systemic exposure than small molecule, antibody or human cell-based therapies, potentially reducing the risk of non-specific auto-immune reactions. Our technology produces single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal and pancreatic tumors and has also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models. We have recently filed an Investigational New Drug, or an IND, application with the U.S. Food and Drug Administration and plan to commence a Phase 1 clinical trial in the second half of 2022 targeting solid tumors, after the IND application becomes effective. Target indications include, but not limited to, colorectal, hepatocellular (± HBV), bladder, cervical and pancreatic carcinoma.

Decoy Merger

On August 3, 2021, we completed our merger with Decoy following the satisfaction or waiver of the conditions set forth in the Merger Agreement, dated as of March 15, 2021 among the Company, Decoy, Intec Israel, Domestication Merger Sub Ltd., an Israeli company and a wholly-owned subsidiary of the Company, or Domestication Merger Sub, and Dillon Merger Subsidiary Inc., a Delaware corporation and wholly owned subsidiary of the Company, or Merger Sub, pursuant to which Merger Sub merged with and into Decoy, with Decoy surviving as a wholly owned subsidiary of the Company, or the Merger, and the business conducted by Decoy became the business conducted by the combined company.

Previously, on July 27, 2021, we, Intec Israel and Domestication Merger Sub completed the previously announced domestication merger pursuant to the terms and conditions of the Domestication Merger Agreement, whereby Domestication Merger Sub merged with and into Intec Israel, with Intec Israel being the surviving entity and a wholly-owned subsidiary of ours. At the time of the Domestication Merger, Intec Israel continued to possess all of its assets, rights, powers and property as constituted immediately prior to the Domestication Merger and continued to be subject to all of its debts, liabilities and obligations as constituted immediately prior to the Domestication Merger.

Also, in connection with the Merger, we changed our name from “Intec Parent, Inc.” to “Indaptus Therapeutics, Inc.”.

Following completion of the Merger, our shares of common stock commenced trading at market open on August 4, 2021, on the Nasdaq Capital Market under the name “Indaptus Therapeutics, Inc.” and ticker symbol “INDP” and under the new CUSIP 45339J 105.

Winding Down of Accordion Pill Business

In connection with the completion of the Merger, on August 4, 2021, our board of directors determined to wind down the Accordion Pill business of Intec Israel which was completed as of the date of issuance of these consolidated financial statements.

In connection with the winding down, we laid off all our employees and we terminated our contracts with counterparties, including the termination of the Process Development Agreement between Intec Israel and LTS Lohmann Therapie Systeme AG, and the termination of the unprotected lease agreement between Intec Israel and its landlord for the lease of offices located in Jerusalem, Israel.

Private Placement

In connection with the Merger, on July 23, 2021, or the Signing Date, we entered into a securities purchase agreement, or the Purchase Agreement, with a certain institutional investor, or the Purchaser, pursuant to which we agreed to sell and issue, in a private placement, or the Private Placement, a pre-funded warrant to purchase up to 2,727,273 shares of our common stock, or the Pre-funded Warrant, and a warrant to purchase up to 2,727,273 of our common stock at a purchase price of $10.99 per Pre-funded Warrant and associated Warrant, for aggregate gross proceeds to us of approximately $30.0 million, before deducting the placement agent’s fees and other offering expenses payable by the Company. The Warrant has a term of five and one-half years, is exercisable immediately following the issuance date and has an exercise price of $11.00 per share, subject to adjustment as set forth therein.

On August 3, 2021, the Private Placement closed and in September 2021, the Pre-Funded Warrants were fully exercised. In addition, we issued to the placement agent a warrant to purchase 136,364 shares of our common stock at an exercise price of $13.75.

In connection with the Purchase Agreement, we entered into a registration rights agreement, or the Registration Rights Agreement, with the Purchaser requiring us to file a resale registration statement, or the Resale Registration Statement, with the SEC to register for resale of the shares of our common stock issuable upon exercise of the Pre-Funded Warrant and Warrant. We subsequently filed a registration statement registering for resale the shares of our common stock issuable upon exercise of the Pre-Funded Warrant and Warrant which became effective on September 29, 2021.

Components of Operating Results

Operating Expenses

Research and Development

Research and development expenses account for a significant portion of our operating expenses. Research and development expenses consist primarily of fees paid to contract research organizations, or CROs, and contract manufacturing organizations, or CMOs, as well as compensation expenses for certain employees involved in the planning, managing, and analyzing the work of the CROs and CMOs.

We expect our research and development expenses to increase substantially for the foreseeable future as we continue to ramp up our clinical development activities and incur expenses associated with hiring additional personnel to support our research and development efforts. Our expenditures on future nonclinical and clinical development programs are subject to numerous uncertainties in timing and cost to completion. The duration, costs and timing of pre-clinical studies and clinical trials and development of product candidates will depend on a variety of factors, including:

	●	the timing and receipt of regulatory approvals;
	●	the scope, rate of progress and expenses of pre-clinical studies and clinical trials and other research and development activities;
	●	potential safety monitoring and other studies requested by regulatory agencies;
	●	significant and changing government regulation.

General and Administrative

General and administrative expenses include compensation, employee benefits, and stock-based compensation for executive management, finance administration and human resources, facility costs (including rent), professional service fees, and other general overhead costs, including depreciation, to support our operations.

We expect our general and administrative expenses to increase substantially for the foreseeable future as we continue to increase our headcount to support our research and development activities and operations generally, the growth of our business and, if any of our product candidates receive marketing approval, commercialization activities. We also expect to continue to incur additional expenses as a result of operating as a public company, including expenses related to compliance with the rules and regulations of the SEC, additional director and officer insurance expenses, investor relations activities and other administrative and professional services.

Other Income, Net

Other income includes interest earned on deposits and other items of income, expense, gain and loss that are incidental to the core operations of the Company.

Results of Operations

Three months ended March 31, 2022 compared to three months ended March 31, 2021

The following tables sets forth our results of operations for the three months ended March 31, 2022 and 2021 and the relative dollar and percentage change between the two quarters.

	Three months ended						Change
	March 31,						(2022 to 2021)
	2022			2021			($)			%
Operating expenses:
Research and development	$	1,297,098		$	489,721		$	807,377			165	%
General and administrative		2,104,975			124,254			1,980,721			1,594	%

Total operating expenses		3,402,073			613,975			2,788,098			454	%

Loss from operations		(3,402,073	)		(613,975	)		(2,788,098	)		454	%

Other income, net		36,919			1,554			35,365			2,275	%

Net loss	$	(3,365,154	)	$	(612,421	)	$	(2,752,733	)		450	%
Net loss attributable to common stockholders per share, basic and diluted	$	(0.41	)	$	(0.31	)	$	(0.10	)		32	%
Weighted average number of shares used in calculating net loss per share, basic and diluted		8,258,597			1,944,672

Research and Development Expenses

Our research and development expenses for the three months ended March 31, 2022 amounted to approximately $1.3 million, an increase of approximately $800,000, or approximately 165%, compared to approximately $500,000 for the three months ended March 31, 2021. This increase was attributable primarily to (i) an increase of approximately $500,000 for payroll and related expenses including approximately $160,000 of stock-based compensation, and (ii) an increase of approximately $300,000 for the phase 1 clinical trial preparation and the preparation of the IND that was recently filed. We expect our research and development expenses to increase substantially for the reminder of the year as we plan to commence a Phase 1 clinical trial after the IND application becomes effective.

General and Administrative Expenses

Our general and administrative expenses for the three months ended March 31, 2022 amounted to approximately $2.1 million, an increase of approximately $2.0 million, or approximately 1,594%, compared to approximately $0.1 million for the three months ended March 31, 2021. This increase was attributable primarily to (i) an increase of approximately $1.1 million for payroll and related expenses, including approximately $650,000 of stock-based compensation, resulting from increased headcount of our executive team following the Merger and (ii) approximately $750,000 increase in directors and officers’ insurance policy and professional fees associated with being a public company following the Merger. We expect our general and administrative expenses to increase for the reminder of the year as we continue to support our research and development activities.

Other Income, net

Other income, net, increased in the three months ended March 31, 2022 compared to the same period in 2021 primarily as a result of proceeds received in excess of the estimated fair value of assets held for sale.

Liquidity and Resources

Since our inception, we have funded our operations primarily through public and private offerings of our equity securities. As of March 31, 2022, we had cash and cash equivalents and marketable securities of approximately $36.2 million. As of December 31, 2021, we had cash and cash equivalents of approximately $39.1 million.

In August 2021, we sold a Pre-funded Warrant to purchase 2,727,273 of our common stock and a Warrant to purchase 2,727,273 of our common stock in a private placement. The Warrant is exercisable at an exercise price of $11.00 per share. In September 2021, the Pre-funded Warrant was fully exercised at an exercise price of $0.01 per share. The Pre-funded Warrant and the Warrant were sold together at a combined price of $11.00, including the pre-funded exercise price. The total net proceeds were approximately $27.3 million, after deducting placement agent fees and offering expenses in the amount of approximately $2.7 million.

Net cash used in operating activities was approximately $3.1 million for the three months ended March 31, 2022, compared with net cash used in operating activities of approximately $0.8 million for the for the three months ended March 31, 2021. This increase resulted primarily from an increase in general and administrative expenses and effects of the Merger and changes in operating assets and liabilities.

Net cash used in investing activities was approximately $2.8 million for the three months ended March 31, 2022 which was primarily due to the purchase of marketable securities investments during that period. There was no net cash provided by or used in investing activities in the three months ended March 31, 2021.

There was no net cash provided by financing activities in the three months ended March 31, 2022. Net cash provided by financing activities was approximately $3.7 million for the three months ended March 31, 2021 following the issuance of a series of Simple Agreements for Future Equity (SAFEs) to accredited investors.

Current Outlook

Following the Private Placement that closed in August 2021, we believe that we have adequate cash to fund our ongoing activities for more than one year from the date of this Quarterly Report on Form 10-Q.

We are closely monitoring ongoing developments in connection with the COVID-19 pandemic. As of the date of issuance of these condensed consolidated financial statements, the ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. While it is unknown how long these conditions will last and what the complete financial effect will be to us, capital raise efforts and additional development of our technologies may be negatively affected.

Developing drugs, conducting clinical trials, obtaining commercial manufacturing capabilities and commercializing products is expensive and we will need to raise substantial additional funds to achieve our strategic objectives. We will require significant additional financing in the future to fund our operations, including if and when we progress into additional clinical trials, obtain regulatory approval for one or more of our product candidates, obtain commercial manufacturing capabilities and commercialize one or more of our product candidates. Our future capital requirements will depend on many factors, including, but not limited to:

	●	the progress and costs of our preparations for clinical trials and other research and development activities;

	●	the scope, prioritization and number of clinical trials and other research and development programs;

	●	the amount of revenues and contributions we receive under future licensing, collaboration, development and commercialization arrangements with respect to our product candidates;

	●	the impact of the COVID-19 pandemic;

	●	the costs of the development and expansion of our operational infrastructure;

	●	the costs and timing of obtaining regulatory approval for one or more of our product candidates;

	●	the ability of us, or our collaborators, to achieve development milestones, marketing approval and other events or developments under our potential future licensing agreements;

	●	the costs of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights;

	●	the costs and timing of securing manufacturing arrangements for clinical or commercial production;

	●	the costs of contracting with third parties to provide sales and marketing capabilities for us or establishing such capabilities ourselves;

	●	the costs of acquiring or undertaking development and commercialization efforts for any future products, product candidates or technology;

	●	the magnitude of our general and administrative expenses;

	●	market conditions; and

	●	any cost that we may incur under future in- and out-licensing arrangements relating to one or more of our product candidates.

Until we can generate significant recurring revenues, we expect to satisfy our future cash needs through capital raising. We cannot be certain that additional funding will be available to us on acceptable terms, if at all. If funds are not available, we may be required to delay, reduce the scope of or eliminate research or development programs and other operations and make necessary change to our operations to reduce the level of our expenditures in line with available resources.

We have no off-balance sheet arrangements that have had or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

Critical Accounting Estimates

This discussion and analysis of our financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these condensed consolidated financial statements requires us to make estimates that affect the reported amounts of our assets, liabilities and expenses. Significant accounting policies employed by us, including the use of estimates, are presented in our annual financial statements for the year ended December 31, 2021, and their accompanying notes included in the Annual Report on Form 10-K for the year ended December 31, 2021 filed with the SEC. We periodically evaluate our estimates, which are based on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Critical accounting policies are those that are most important to the portrayal of our financial condition and results of operations and require our subjective or complex judgments, resulting in the need to make estimates about the effect of matters that are inherently uncertain. If actual performance should differ from historical experience or if the underlying assumptions were to change, our financial condition and results of operations may be materially impacted.

We believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our financial statements.

Accounting for Research and Development Costs

We record the costs associated with services provided by CROs and CMOs as they are incurred. Though the scope and timing of work are generally based on signed agreements, some judgement is involved in determining periodic expenses because payment flows do not always match the periods over which services and materials are provided to us. As a result, our management is required to make estimates of services received and efforts expended pursuant to agreements established with these third-parties at each period-end date. During the three months ended March 31, 2022, we incurred approximately $1.1 million of research and development expenses. As of March 31, 2022, we recorded an accrued liability of $0.2 million for expenses incurred, but not yet invoiced, and a prepaid expense of $0.1 million for payments made that relate to future periods. Over or under estimating the services received or efforts expended could cause us to overstate or understate research and development expenses incurred within a reporting period, and related accrued and prepaid expenses.

Stock-Based Compensation

We measure and record the expense related to stock-based payment awards based on the fair value of those awards on the date of grant. We use the Black-Scholes-Merton, or Black-Scholes, option pricing model to establish the fair value. We recognize stock-based compensation expense over the requisite service period of the individual grant, generally equal to the vesting period, on a straight-line basis. The Black Scholes model requires that our management make certain estimates regarding the expected stock price volatility, expected term, risk–free interest rate, and dividend yield to derive an estimated fair value. The use of different assumptions would increase or decrease the related determination of fair value, increasing or decreasing the compensation expense related to a particular stock-based award.

Recently Issued Accounting Pronouncements

None.

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

Not required for smaller reporting companies.

Item 4.

Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can only provide reasonable assurance of achieving the desired control objectives, and in reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we have evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of March 31, 2022. Based on that evaluation, our principal executive officer and principal financial officer have concluded that as of March 31, 2022, these disclosure controls and procedures were effective at the reasonable assurance level.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting identified in connection with the evaluation required by Rule 13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the quarter ended March 31, 2022 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1.

Legal Proceedings

From time to time, we may become involved in various lawsuits and legal proceedings, which arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. There are currently no pending material legal proceedings, and we are currently not aware of any legal proceedings or claims against us or our property that we believe will have any significant effect on our business, financial position or operating results. None of our officers or directors is a party against us in any legal proceeding.

Item1A.

Risk Factors

Not required for a smaller reporting company.

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3.

Defaults Upon Senior Securities

None.

Item 4.

Mine Safety Disclosures

Not applicable.

Item 5.

Other Information

None.

Item 6.

Exhibits

Exhibit No.		Exhibit Description

3.1		Amended and Restated Certificate of Incorporation of Indaptus Therapeutics, Inc., dated as of July 23, 2021 (incorporated herein by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on July 23, 2021)

3.2		Amended and Restated Bylaws of Indaptus Therapeutics, Inc., dated as of July 23, 2021 (incorporated herein by reference to Exhibit 3.2 of the Company’s Current Report on Form 8-K filed with the SEC on July 23, 2021)

3.3		Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Indaptus Therapeutics, Inc. dated August 3, 2021 (incorporated herein by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K filed with the SEC on August 6, 2021)

31.1*		Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended

31.2*		Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a), promulgated under the Securities Exchange Act of 1934, as amended

32.1#		Certification of Principal Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2#		Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS*		Inline XBRL Instance Document

101.SCH*		Inline XBRL Taxonomy Extension Schema Document

101.CAL*		Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*		Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB*		Inline XBRL Taxonomy Extension Labels Linkbase Document

101.PRE*		Inline XBRL Taxonomy Extension Presentation Linkbase Document

104		Cover Page Interactive Data File (formatted as Inline XBRL document and included in Exhibit 101)

*	Filed herewith
#	Furnished herewith

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Indaptus Therapeutics, Inc.

Date: May 12, 2022	By:	/s/ Jeffrey A. Meckler
		Jeffrey A. Meckler
		Chief Executive Officer (Principal Executive Officer)

Date: May 12, 2022	By:	/s/ Nir Sassi
		Nir Sassi
		Chief Financial Officer (Principal Financial and Accounting Officer)

EX-31.1 2 ex31-1.htm

Exhibit 31.1

CERTIFICATIONS

I, Jeffrey A. Meckler, certify that:

	1.	I have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2022 of Indaptus Therapeutics, Inc. (the “registrant”);

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent functions):

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 12, 2022

/s/ Jeffrey A. Meckler

Jeffrey A. Meckler

Chief Executive Officer

EX-31.2 3 ex31-2.htm

Exhibit 31.2

CERTIFICATIONS

I, Nir Sassi, certify that:

	1.	I have reviewed this Quarterly Report on Form 10-Q for the period ended March 31, 2022 of Indaptus Therapeutics, Inc. (the “registrant”);

	2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

	3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

	4.	The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f)and 15d-15(f)) for the registrant and have:

	a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

	b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

	c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

	d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

	a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

	b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: May 12, 2022

/s/ Nir Sassi

Nir Sassi

Chief Financial Officer

EX-32.1 4 ex32-1.htm

Exhibit 32.1

Indaptus Therapeutics, Inc.

Certification Pursuant to

18 U.S.C. Section 1350,

as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Indaptus Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jeffrey A. Meckler, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(a)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(b)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Jeffrey A. Meckler
Jeffrey A. Meckler
Chief Executive Officer

Date: May 12, 2022

EX-32.2 5 ex32-2.htm

Exhibit 32.2

Indaptus Therapeutics, Inc.

Certification Pursuant to

18 U.S.C. Section 1350,

as Adopted Pursuant to

Section 906 of the Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report of Indaptus Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Nir Sassi, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(a)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(b)	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ Nir Sassi
Nir Sassi
Chief Financial Officer

Date: May 12, 2022

EX-101.SCH 6 indp-20220331.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Condensed Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 00000007 - Disclosure - GENERAL link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - MARKETABLE SECURITIES link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - CAPITALIZATION link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - GENERAL (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - SCHEDULE OF ANTI-DILUTIVE SECURITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - MARKETABLE SECURITIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - SCHEDULE OF PREPAID EXPENSE AND OTHER CURRENT ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - SCHEDULE OF SHARE BASED COMPENSATION (Details) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION EXPENSES (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED (Details) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - CAPITALIZATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - SUMMARY OF MINIMUM LEASE PAYMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 7 indp-20220331_cal.xml XBRL CALCULATION FILE EX-101.DEF 8 indp-20220331_def.xml XBRL DEFINITION FILE EX-101.LAB 9 indp-20220331_lab.xml XBRL LABEL FILE Equity Components [Axis] Preferred Stock [Member] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Sale of Stock [Axis] Shareholders Equity Post Reverse Share Split [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Purchase Agreements [Member] Private Placement [Member] Legal Entity [Axis] Indaptus [Member] Antidilutive Securities [Axis] Equity Option [Member] Warrant [Member] Asset Class [Axis] Property, Plant and Equipment [Member] Long-Lived Tangible Asset [Axis] Computers and Other Office Equipment [Member] Furniture [Member] Plan Name [Axis] 2021 Plan [Member] Title of Individual [Axis] Executive Officer [Member] Employee [Member] Income Statement Location [Axis] Research and Development Expense [Member] General and Administrative Expense [Member] Exercise Price Range [Axis] Exercise Price Range One [Member] Exercise Price Range Two [Member] Exercise Price Range Three [Member] Geographical [Axis] CANADA Two Year Lease Agreement [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Statement of Financial Position [Abstract] Assets Current assets: Cash and cash equivalents Marketable securities Assets held for sale Prepaid expenses and other current assets Total current assets Non-current assets: Property and equipment, net Right-of-use asset Other assets Total non-current assets Total assets Liabilities and stockholders’ equity Current liabilities: Accounts payable and other current liabilities Operating lease liability, current portion Total current liabilities Non-current liabilities: Operating lease liability, net of current portion Total non-current liabilities Total liabilities Commitments and contingent liabilities (Note 8) Stockholders’ equity: Common stock: $0.01 par value, 200,000,000 shares authorized as of March 31, 2022 and December 31, 2021; 8,258,597 shares issued and outstanding as of March 31, 2022 and December 31, 2021 Additional paid in capital Accumulated deficit Accumulated other comprehensive loss Total stockholders’ equity Total liabilities and stockholders’ equity Common stock, par value Common stock, shares authorized Common stock, shares issued Common stock, shares outstanding Income Statement [Abstract] Operating expenses: Research and development General and administrative Total operating expenses Loss from operations Other income, net Net loss Net loss available to common stockholders per share of common stock, basic and diluted Weighted average number of shares used in calculating net loss per share, basic and diluted Net loss Other comprehensive loss: Unrealized loss on available-for-sale securities Comprehensive loss Statement [Table] Statement [Line Items] Beginning balance, value Beginning balance, shares Stock-based compensation Other comprehensive loss Ending balance, value Ending balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Adjustments to reconcile net loss to net cash used in operating activities: Depreciation Stock-based compensation Realized gain on assets held for sale Changes in operating assets and liabilities: Prepaid expenses and other current assets Accounts payable and other current liabilities Deferred transaction costs Operating lease right-of-use asset and liability, net Net cash used in operating activities Cash flows from investing activities: Proceeds received for assets held for sale Purchase of marketable securities Net cash used in investing activities Cash flows from financing activities: Proceeds from SAFEs, net Net cash provided by financing activities Net (decrease) increase in cash and cash equivalents Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Supplemental cash flow disclosures Cash paid for income taxes Cash received for interest earned on deposits Organization, Consolidation and Presentation of Financial Statements [Abstract] GENERAL Accounting Policies [Abstract] SIGNIFICANT ACCOUNTING POLICIES Investments, Debt and Equity Securities [Abstract] MARKETABLE SECURITIES Prepaid Expenses And Other Current Assets PREPAID EXPENSES AND OTHER CURRENT ASSETS Payables and Accruals [Abstract] ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES Share-Based Payment Arrangement [Abstract] STOCK-BASED COMPENSATION Capitalization CAPITALIZATION Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Subsequent Events [Abstract] EX-101.PRE 10 indp-20220331_pre.xml XBRL PRESENTATION FILE XML 11 R1.htm IDEA: XBRL DOCUMENT

Cover - shares	3 Months Ended
Cover - shares	Mar. 31, 2022	May 10, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2022
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2022
Current Fiscal Year End Date	--12-31
Entity File Number	001-40652
Entity Registrant Name	Indaptus Therapeutics, Inc.
Entity Central Index Key	0001857044
Entity Tax Identification Number	86-3158720
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	3 Columbus Circle
Entity Address, Address Line Two	15th Floor
Entity Address, City or Town	New York
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	10019
City Area Code	347
Local Phone Number	480 9760
Trading Symbol	INDP
Security Exchange Name	NASDAQ
Title of 12(g) Security	Common stock, par value $0.01 per share
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		8,258,597

XML 12 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 33,216,311	$ 39,132,165
Marketable securities	2,961,460
Assets held for sale		148,400
Prepaid expenses and other current assets	741,945	1,106,653
Total current assets	36,919,716	40,387,218
Non-current assets:
Property and equipment, net	3,266	3,800
Right-of-use asset	147,102	169,088
Other assets	16,477	16,477
Total non-current assets	166,845	189,365
Total assets	37,086,561	40,576,583
Current liabilities:
Accounts payable and other current liabilities	3,582,472	4,507,676
Operating lease liability, current portion	97,185	96,465
Total current liabilities	3,679,657	4,604,141
Non-current liabilities:
Operating lease liability, net of current portion	50,516	72,862
Total non-current liabilities	50,516	72,862
Total liabilities	3,730,173	4,677,003
Commitments and contingent liabilities (Note 8)
Stockholders’ equity:
Common stock: $0.01 par value, 200,000,000 shares authorized as of March 31, 2022 and December 31, 2021; 8,258,597 shares issued and outstanding as of March 31, 2022 and December 31, 2021	82,586	82,586
Additional paid in capital	52,319,064	51,487,881
Accumulated deficit	(19,036,041)	(15,670,887)
Accumulated other comprehensive loss	(9,221)
Total stockholders’ equity	33,356,388	35,899,580
Total liabilities and stockholders’ equity	$ 37,086,561	$ 40,576,583

XML 13 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Common stock, par value	$ 0.01	$ 0.01
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	8,258,597	8,258,597
Common stock, shares outstanding	8,258,597	8,258,597

XML 14 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating expenses:
Research and development	$ 1,297,098	$ 489,721
General and administrative	2,104,975	124,254
Total operating expenses	3,402,073	613,975
Loss from operations	(3,402,073)	(613,975)
Other income, net	36,919	1,554
Net loss	$ (3,365,154)	$ (612,421)
Net loss available to common stockholders per share of common stock, basic and diluted	$ (0.41)	$ (0.31)
Weighted average number of shares used in calculating net loss per share, basic and diluted	8,258,597	1,944,672
Net loss	$ (3,365,154)	$ (612,421)
Other comprehensive loss:
Unrealized loss on available-for-sale securities	(9,221)
Comprehensive loss	$ (3,374,375)	$ (612,421)

XML 15 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Beginning balance, value at Dec. 31, 2020	$ 8,359	$ 19,447	$ 7,693,994	$ (7,959,501)		$ (237,701)
Beginning balance, shares at Dec. 31, 2020	835,928	1,944,672
Stock-based compensation			20,445			20,445
Net loss				(612,421)		(612,421)
Other comprehensive loss
Ending balance, value at Mar. 31, 2021	$ 8,359	$ 19,447	7,714,439	(8,571,922)		(829,677)
Ending balance, shares at Mar. 31, 2021	835,928	1,944,672
Beginning balance, value at Dec. 31, 2021		$ 82,586	51,487,881	(15,670,887)		35,899,580
Beginning balance, shares at Dec. 31, 2021		8,258,597
Stock-based compensation			831,183			831,183
Net loss				(3,365,154)		(3,365,154)
Other comprehensive loss					(9,221)	(9,221)
Ending balance, value at Mar. 31, 2022		$ 82,586	$ 52,319,064	$ (19,036,041)	$ (9,221)	$ 33,356,388
Ending balance, shares at Mar. 31, 2022		8,258,597

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 4
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 40
-Section 65
-Paragraph 1
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 50
-Paragraph 6
-URI https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 3
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580

Reference 25: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 470
-SubTopic 10
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-Subparagraph (b)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599

+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 852
-SubTopic 10
-Section 55
-Paragraph 10
-URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 28
-Subparagraph (f)
-URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 323
-SubTopic 10
-Section 50
-Paragraph 3
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571

+ Details

XML 16 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Cash flows from operating activities:
Net loss	$ (3,365,154)	$ (612,421)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	534	213
Stock-based compensation	831,183	20,445
Realized gain on assets held for sale	(24,155)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	364,708	(109,883)
Accounts payable and other current liabilities	(925,204)	481,050
Deferred transaction costs		(604,988)
Operating lease right-of-use asset and liability, net	360
Net cash used in operating activities	(3,117,728)	(825,584)
Cash flows from investing activities:
Proceeds received for assets held for sale	172,555
Purchase of marketable securities	(2,970,681)
Net cash used in investing activities	(2,798,126)
Cash flows from financing activities:
Proceeds from SAFEs, net		3,675,000
Net cash provided by financing activities		3,675,000
Net (decrease) increase in cash and cash equivalents	(5,915,854)	2,849,416
Cash and cash equivalents at beginning of period	39,132,165	1,637,499
Cash and cash equivalents at end of period	33,216,311	4,486,915
Supplemental cash flow disclosures
Cash paid for income taxes		800
Cash received for interest earned on deposits	$ 1,318	$ 506

XML 17 R7.htm IDEA: XBRL DOCUMENT

GENERAL

3 Months Ended

Mar. 31, 2022

Organization, Consolidation and Presentation of Financial Statements [Abstract]

GENERAL

NOTE 1: GENERAL

Risks and uncertainties

Going concern and management’s plans

XML 18 R8.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2022

Accounting Policies [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 2: SIGNIFICANT ACCOUNTING POLICIES

Basis of presentation

The results for the three-month period ended March 31, 2022, are not necessarily indicative of the results expected for the year ending December 31, 2022.

Principles of consolidation

The consolidated financial statements include the accounts of Indaptus and its subsidiaries. Intercompany balances and transactions have been eliminated upon consolidation.

Use of estimates

Loss per share

SCHEDULE OF ANTI-DILUTIVE SECURITIES

	2022		2021
	For the three months ended March 31,
	2022		2021
Outstanding stock options		1,580,623		206,079
Warrants		3,090,787		-
Anti-dilutive securities		3,090,787		-

Cash and cash equivalents

Marketable securities

Property and equipment

Patents

Research and development expenses

Income taxes

Stock-based compensation

Dividend Yield—The Company has not declared or paid dividends to date and does not anticipate declaring dividends. As such, the dividend yield has been estimated to be zero.

The Company has elected to recognize forfeitures as they occur.

Fair value measurements

The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:

Level 1:	Quoted prices in active markets for identical assets or liabilities.

Level 2:	Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.

Level 3:	Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

XML 19 R9.htm IDEA: XBRL DOCUMENT

MARKETABLE SECURITIES

3 Months Ended

Mar. 31, 2022

Investments, Debt and Equity Securities [Abstract]

MARKETABLE SECURITIES

NOTE 3: MARKETABLE SECURITIES

As of March 31, 2022, the amount of the marketable securities is $2,961,460. As of December 31, 2021, the Company had no marketable securities.

The unrealized losses for the three-month period ended March 31, 2022 amounted to $9,221.

XML 20 R10.htm IDEA: XBRL DOCUMENT

PREPAID EXPENSES AND OTHER CURRENT ASSETS

3 Months Ended

Mar. 31, 2022

Prepaid Expenses And Other Current Assets

PREPAID EXPENSES AND OTHER CURRENT ASSETS

NOTE 4: PREPAID EXPENSES AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets are comprised of the following:

	March 31,		December 31,
	2022		2021
Prepaid insurance	$	543,986	$	945,023
Prepaid research and development		78,353		127,643
Other receivables		-		21,056
Other prepaid expenses		119,606		12,931
Total prepaid expenses and other current assets	$	741,945	$	1,106,653

XML 21 R11.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES

3 Months Ended

Mar. 31, 2022

Payables and Accruals [Abstract]

ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES

NOTE 5: ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES

Accounts payable and other current liabilities are comprised of the following:

	March 31,		December 31,
	2022		2021
Accounts payable	$	2,834,683	$	2,637,806
Accrued employee costs		276,285		1,371,136
Accrued professional fees		71,186		139,871
Accrued research and development		175,978		135,751
Accrued board fees		116,000		125,333
Delaware franchise taxes payable		50,000		-
Other accrued expenses		58,340		97,778
Total accounts payable and other current liabilities	$	3,582,472	$	4,507,676

XML 22 R12.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION

3 Months Ended

Mar. 31, 2022

Share-Based Payment Arrangement [Abstract]

STOCK-BASED COMPENSATION

NOTE 6: STOCK-BASED COMPENSATION

A summary of the stock option activity during the three months ended March 31, 2022, is presented in the table below:

SCHEDULE OF SHARE BASED COMPENSATION

				Weighted average
	Number of options			Exercise price		Remaining contractual life (in years)		Intrinsic value
Outstanding as of January 1, 2022		1,174,600		$	17.10		9.1	$	241,103
Granted		439,200		$	4.82		9.8	$	-
Exercised		-		$	-		-	$	-
Forfeited and cancelled		(33,237	)	$	11.46		9.3	$	-
Outstanding as of March 31, 2022		1,580,623		$	13.80		9.2	$	96,870
Exercisable as of March 31, 2022		127,749		$	81.20		6.3	$	96,870
Vested and expected to vest March 31, 2022		1,580,623		$	13.80		9.2	$	96,870

	2022		2021
	For the three months ended March 31,
	2022		2021
Research and development	$	170,163	$	8,189
General and administrative		661,020		12,256
Total stock-based compensation expense	$	831,183	$	20,445

	2022
Stock price	$	4.82
Exercise price	$	4.82
Expected term (in years)		5.9
Volatility		105.5	%
Risk free rate		1.7	%
Dividend yield		0.0	%

The following table presents the exercise price of outstanding stock options as of March 31, 2022:

Exercise price	Options outstanding
$0.01 - $8.00		539,925
$8.01 - $16.00		1,006,000
$16.00 or higher		34,698
Total		1,580,623

XML 23 R13.htm IDEA: XBRL DOCUMENT

CAPITALIZATION

3 Months Ended

Mar. 31, 2022

Capitalization

CAPITALIZATION

NOTE 7: CAPITALIZATION

	a.	As of March 31, 2022 and December 31, 2021, the Company had 200,000,000 shares of common stock authorized and 8,258,597 shares of common stock issued and outstanding.

	b.	As of March 31, 2022 and December 31, 2021, there were warrants outstanding to purchase an aggregate of 3,090,787 shares of common stock of Indaptus. As of March 31, 2022, these warrants are exercisable at a weighted average price of $12.50 and their weighted average remaining contractual term is 4.7 years.

XML 24 R14.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Mar. 31, 2022

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 8: COMMITMENTS AND CONTINGENCIES

Litigation

Leases

Future minimum annual lease payments under the Company’s noncancelable operating lease as of March 31, 2022 are as follows:

SUMMARY OF MINIMUM LEASE PAYMENTS

2		2022
2022	$	72,469
2023		82,387
Total minimum lease payments		154,856
Less: amount representing interest		(7,155	)
Present value of operating lease liability		147,701
Less: current portion		(97,185	)
Operating lease liability, net of current portion	$	50,516

XML 25 R15.htm IDEA: XBRL DOCUMENT

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2022

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 9: SUBSEQUENT EVENTS

XML 26 R16.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2022

Accounting Policies [Abstract]

Basis of presentation

Basis of presentation

The results for the three-month period ended March 31, 2022, are not necessarily indicative of the results expected for the year ending December 31, 2022.

Principles of consolidation

Principles of consolidation

The consolidated financial statements include the accounts of Indaptus and its subsidiaries. Intercompany balances and transactions have been eliminated upon consolidation.

Use of estimates

Use of estimates

Loss per share

Loss per share

SCHEDULE OF ANTI-DILUTIVE SECURITIES

	2022		2021
	For the three months ended March 31,
	2022		2021
Outstanding stock options		1,580,623		206,079
Warrants		3,090,787		-
Anti-dilutive securities		3,090,787		-

Cash and cash equivalents

Cash and cash equivalents

Marketable securities

Marketable securities

Property and equipment

Property and equipment

Patents

Patents

Research and development expenses

Research and development expenses

Income taxes

Income taxes

Stock-based compensation

Stock-based compensation

Dividend Yield—The Company has not declared or paid dividends to date and does not anticipate declaring dividends. As such, the dividend yield has been estimated to be zero.

The Company has elected to recognize forfeitures as they occur.

Fair value measurements

Fair value measurements

The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes:

Level 1:	Quoted prices in active markets for identical assets or liabilities.

Level 2:	Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.

Level 3:	Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.

New Accounting Pronouncements, Policy [Policy Text Block]

XML 27 R17.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Mar. 31, 2022

Accounting Policies [Abstract]

SCHEDULE OF ANTI-DILUTIVE SECURITIES

	2022		2021
	For the three months ended March 31,
	2022		2021
Outstanding stock options		1,580,623		206,079
Warrants		3,090,787		-
Anti-dilutive securities		3,090,787		-

XML 28 R18.htm IDEA: XBRL DOCUMENT

PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)

3 Months Ended

Mar. 31, 2022

Prepaid Expenses And Other Current Assets

SCHEDULE OF PREPAID EXPENSE AND OTHER CURRENT ASSETS

Prepaid expenses and other current assets are comprised of the following:

	March 31,		December 31,
	2022		2021
Prepaid insurance	$	543,986	$	945,023
Prepaid research and development		78,353		127,643
Other receivables		-		21,056
Other prepaid expenses		119,606		12,931
Total prepaid expenses and other current assets	$	741,945	$	1,106,653

XML 29 R19.htm IDEA: XBRL DOCUMENT

ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Tables)

3 Months Ended

Mar. 31, 2022

Payables and Accruals [Abstract]

SCHEDULE OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES

Accounts payable and other current liabilities are comprised of the following:

	March 31,		December 31,
	2022		2021
Accounts payable	$	2,834,683	$	2,637,806
Accrued employee costs		276,285		1,371,136
Accrued professional fees		71,186		139,871
Accrued research and development		175,978		135,751
Accrued board fees		116,000		125,333
Delaware franchise taxes payable		50,000		-
Other accrued expenses		58,340		97,778
Total accounts payable and other current liabilities	$	3,582,472	$	4,507,676

XML 30 R20.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Tables)

3 Months Ended

Mar. 31, 2022

Share-Based Payment Arrangement [Abstract]

SCHEDULE OF SHARE BASED COMPENSATION

A summary of the stock option activity during the three months ended March 31, 2022, is presented in the table below:

SCHEDULE OF SHARE BASED COMPENSATION

				Weighted average
	Number of options			Exercise price		Remaining contractual life (in years)		Intrinsic value
Outstanding as of January 1, 2022		1,174,600		$	17.10		9.1	$	241,103
Granted		439,200		$	4.82		9.8	$	-
Exercised		-		$	-		-	$	-
Forfeited and cancelled		(33,237	)	$	11.46		9.3	$	-
Outstanding as of March 31, 2022		1,580,623		$	13.80		9.2	$	96,870
Exercisable as of March 31, 2022		127,749		$	81.20		6.3	$	96,870
Vested and expected to vest March 31, 2022		1,580,623		$	13.80		9.2	$	96,870

SCHEDULE OF STOCK BASED COMPENSATION EXPENSES

	2022		2021
	For the three months ended March 31,
	2022		2021
Research and development	$	170,163	$	8,189
General and administrative		661,020		12,256
Total stock-based compensation expense	$	831,183	$	20,445

SCHEDULE OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED

	2022
Stock price	$	4.82
Exercise price	$	4.82
Expected term (in years)		5.9
Volatility		105.5	%
Risk free rate		1.7	%
Dividend yield		0.0	%

SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS

Exercise price	Options outstanding
$0.01 - $8.00		539,925
$8.01 - $16.00		1,006,000
$16.00 or higher		34,698
Total		1,580,623

XML 31 R21.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Tables)

3 Months Ended

Mar. 31, 2022

Commitments and Contingencies Disclosure [Abstract]

SUMMARY OF MINIMUM LEASE PAYMENTS

Future minimum annual lease payments under the Company’s noncancelable operating lease as of March 31, 2022 are as follows:

SUMMARY OF MINIMUM LEASE PAYMENTS

2		2022
2022	$	72,469
2023		82,387
Total minimum lease payments		154,856
Less: amount representing interest		(7,155	)
Present value of operating lease liability		147,701
Less: current portion		(97,185	)
Operating lease liability, net of current portion	$	50,516

XML 32 R22.htm IDEA: XBRL DOCUMENT

GENERAL (Details Narrative) - USD ($)	Jul. 26, 2021	Jul. 23, 2021	Mar. 31, 2022	Dec. 31, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Accumulated deficit			$ 19,036,041	$ 15,670,887
Shareholders Equity Post Reverse Share Split [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Intec Israel, Reverse Share Split Conversion Ratio	1-for-4
Private Placement [Member] \| Purchase Agreements [Member] \| Indaptus [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Total net proceeds from issuance of pre-funded warrants and warrants to purchase Indaptus common stock		$ 27,300,000
Issuance expenses		$ 2,700,000
Warrant is exercisable price		$ 11.00
Number of warrants issued to the placement agent		136,364
Exercise price of warrant issued to the placement agent		$ 13.75

XML 33 R23.htm IDEA: XBRL DOCUMENT

SCHEDULE OF ANTI-DILUTIVE SECURITIES (Details) - shares	3 Months Ended
SCHEDULE OF ANTI-DILUTIVE SECURITIES (Details) - shares	Mar. 31, 2022	Mar. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	3,090,787
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	1,580,623	206,079
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities	3,090,787

XML 34 R24.htm IDEA: XBRL DOCUMENT

SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - Property, Plant and Equipment [Member]	12 Months Ended
	Dec. 31, 2021
Computers and Other Office Equipment [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	3 years
Furniture [Member]
Property, Plant and Equipment [Line Items]
Estimated useful life	5 years

XML 35 R25.htm IDEA: XBRL DOCUMENT

MARKETABLE SECURITIES (Details Narrative) - USD ($)	3 Months Ended
MARKETABLE SECURITIES (Details Narrative) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Investments, Debt and Equity Securities [Abstract]
Marketable securities	$ 2,961,460
Unrealized losses on marketable securities	$ 9,221

XML 36 R26.htm IDEA: XBRL DOCUMENT

SCHEDULE OF PREPAID EXPENSE AND OTHER CURRENT ASSETS (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Prepaid Expenses And Other Current Assets
Prepaid insurance	$ 543,986	$ 945,023
Prepaid research and development	78,353	127,643
Other receivables		21,056
Other prepaid expenses	119,606	12,931
Total prepaid expenses and other current assets	$ 741,945	$ 1,106,653

XML 37 R27.htm IDEA: XBRL DOCUMENT

SCHEDULE OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Payables and Accruals [Abstract]
Accounts payable	$ 2,834,683	$ 2,637,806
Accrued employee costs	276,285	1,371,136
Accrued professional fees	71,186	139,871
Accrued research and development	175,978	135,751
Accrued board fees	116,000	125,333
Delaware franchise taxes payable	50,000
Other accrued expenses	58,340	97,778
Total accounts payable and other current liabilities	$ 3,582,472	$ 4,507,676

XML 38 R28.htm IDEA: XBRL DOCUMENT

SCHEDULE OF SHARE BASED COMPENSATION (Details)	3 Months Ended
SCHEDULE OF SHARE BASED COMPENSATION (Details)	Mar. 31, 2022 USD ($) $ / shares shares
Share-Based Payment Arrangement [Abstract]
Outstanding at beginning of the period	1,174,600
Outstanding at beginning of the period, Exercise price \| $ / shares	$ 17.10
Outstanding at beginning of the period, Weighted average remaining contractual life	9 years 1 month 6 days
Outstanding at beginning of the period, Intrinsic value \| $	$ 241,103
Granted	439,200
Granted, exercise price \| $ / shares	$ 4.82
Granted, Weighted average remaining contractual life	9 years 9 months 18 days
Exercised
Forfeited and cancelled	(33,237)
Forfeited and cancelled, exercise price \| $ / shares	$ 11.46
Forfeited and Cancelled, Weighted average remaining contractual life	9 years 3 months 18 days
Outstanding at end of period	1,580,623
Outstanding at end of period, Exercise price \| $ / shares	$ 13.80
Outstanding at end of period, Weighted average remaining contractual life	9 years 2 months 12 days
Outstanding at end of period, intrinsic value \| $	$ 96,870
Exercisable at end of period	127,749
Exercisable at end of period, Exercise price \| $ / shares	$ 81.20
Exercisable at end of period, Weighted average remaining contractual life	6 years 3 months 18 days
Exercisable at end of period, intrinsic value \| $	$ 96,870
Vested and expected to vest	1,580,623
Vested and expected to vest, Exercise price \| $ / shares	$ 13.80
Vested and expected to vest, Weighted average remaining contractual life	9 years 2 months 12 days
Vested and expected to vest, intrinsic value \| $	$ 96,870

XML 39 R29.htm IDEA: XBRL DOCUMENT

SCHEDULE OF STOCK BASED COMPENSATION EXPENSES (Details) - USD ($)	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 831,183	$ 20,445
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	170,163	8,189
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 661,020	$ 12,256

XML 40 R30.htm IDEA: XBRL DOCUMENT

SCHEDULE OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED (Details)	3 Months Ended
	Mar. 31, 2022 $ / shares
Share-Based Payment Arrangement [Abstract]
Stock Price	$ 4.82
Exercise price	$ 4.82
Expected term	5 years 10 months 24 days
Volatility rate	105.50%
Risk free rate	1.70%
Dividend yield	0.00%

XML 41 R31.htm IDEA: XBRL DOCUMENT

SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS (Details)	3 Months Ended
	Mar. 31, 2022 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Outstanding options, number of outstanding options at the end of period \| shares	1,580,623
Exercise Price Range One [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price range lower range limit	$ 0.01
Exercise price range upper range limit	$ 8.00
Outstanding options, number of outstanding options at the end of period \| shares	539,925
Exercise Price Range Two [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price range lower range limit	$ 8.01
Exercise price range upper range limit	$ 16.00
Outstanding options, number of outstanding options at the end of period \| shares	1,006,000
Exercise Price Range Three [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price range lower range limit	$ 16.00
Outstanding options, number of outstanding options at the end of period \| shares	34,698

XML 42 R32.htm IDEA: XBRL DOCUMENT

STOCK-BASED COMPENSATION (Details Narrative) - USD ($)				3 Months Ended
STOCK-BASED COMPENSATION (Details Narrative) - USD ($)	Feb. 25, 2022	Feb. 01, 2022	Jan. 26, 2022	Mar. 31, 2022	Mar. 31, 2021	Jun. 30, 2021
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options granted to purchase of shares				439,200
Options exercisable price				$ 81.20
Stock-based compensation expense				$ 831,183	$ 20,445
Compensation cost not yet recognized related to unvested stock options				$ 6,700,000
Weighted-average period over which unrecognized compensation expense is expected to be recognized				2 years 3 months 18 days
Weighted average grant date fair value of options granted				$ 3.89
Executive Officer [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options granted to purchase of shares	60,000		289,200
Options exercisable price	$ 4.18		$ 4.90
Options expiration period	10 years		10 years
Employee [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Options granted to purchase of shares		90,000
Options exercisable price		$ 4.97
Options expiration period		10 years
2021 Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based Compensation arrangement by share based payment award, number of shares available for grant						1,864,963

XML 43 R33.htm IDEA: XBRL DOCUMENT

CAPITALIZATION (Details Narrative) - $ / shares	3 Months Ended
CAPITALIZATION (Details Narrative) - $ / shares	Mar. 31, 2022	Dec. 31, 2021
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	8,258,597	8,258,597
Common stock, shares outstanding	8,258,597	8,258,597
Warrant [Member]
Warrant outstanding	3,090,787	3,090,787
Weighted average exercise price	$ 12.50
Weighted average, remaining contractual life	4 years 8 months 12 days

XML 44 R34.htm IDEA: XBRL DOCUMENT

SUMMARY OF MINIMUM LEASE PAYMENTS (Details) - USD ($)	Mar. 31, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
2022	$ 72,469
2023	82,387
Total minimum lease payments	154,856
Less: amount representing interest	(7,155)
Present value of operating lease liability	147,701
Less: current portion	(97,185)	$ (96,465)
Operating lease liability, net of current portion	$ 50,516	$ 72,862

XML 45 R35.htm IDEA: XBRL DOCUMENT

COMMITMENTS AND CONTINGENCIES (Details Narrative)		3 Months Ended
COMMITMENTS AND CONTINGENCIES (Details Narrative)	Oct. 01, 2021 USD ($) ft²	Mar. 31, 2022 USD ($)	Mar. 31, 2021 USD ($)
Product Liability Contingency [Line Items]
Rental expense		$ 26,542	$ 6,365
Operating lease payments		$ 26,182	$ 6,365
CANADA \| Two Year Lease Agreement [Member]
Product Liability Contingency [Line Items]
Area of land \| ft²	2,000
Base rent	$ 7,999
Rate of increase in lease rent	3.00%
Lease liability discount rate	7.00%

XML 46 form10q_htm.xml IDEA: XBRL DOCUMENT 0001857044 2022-01-01 2022-03-31 0001857044 2022-05-10 0001857044 2022-03-31 0001857044 2021-12-31 0001857044 2021-01-01 2021-03-31 0001857044 us-gaap:PreferredStockMember 2020-12-31 0001857044 us-gaap:CommonStockMember 2020-12-31 0001857044 us-gaap:AdditionalPaidInCapitalMember 2020-12-31 0001857044 us-gaap:RetainedEarningsMember 2020-12-31 0001857044 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0001857044 2020-12-31 0001857044 us-gaap:PreferredStockMember 2021-12-31 0001857044 us-gaap:CommonStockMember 2021-12-31 0001857044 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001857044 us-gaap:RetainedEarningsMember 2021-12-31 0001857044 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001857044 us-gaap:PreferredStockMember 2021-01-01 2021-03-31 0001857044 us-gaap:CommonStockMember 2021-01-01 2021-03-31 0001857044 us-gaap:AdditionalPaidInCapitalMember 2021-01-01 2021-03-31 0001857044 us-gaap:RetainedEarningsMember 2021-01-01 2021-03-31 0001857044 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-03-31 0001857044 us-gaap:PreferredStockMember 2022-01-01 2022-03-31 0001857044 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001857044 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001857044 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001857044 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001857044 us-gaap:PreferredStockMember 2021-03-31 0001857044 us-gaap:CommonStockMember 2021-03-31 0001857044 us-gaap:AdditionalPaidInCapitalMember 2021-03-31 0001857044 us-gaap:RetainedEarningsMember 2021-03-31 0001857044 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-03-31 0001857044 2021-03-31 0001857044 us-gaap:PreferredStockMember 2022-03-31 0001857044 us-gaap:CommonStockMember 2022-03-31 0001857044 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001857044 us-gaap:RetainedEarningsMember 2022-03-31 0001857044 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001857044 INDP:ShareholdersEquityPostReverseShareSplitMember 2021-07-25 2021-07-26 0001857044 us-gaap:PrivatePlacementMember INDP:PurchaseAgreementsMember INDP:IndaptusMember 2021-07-22 2021-07-23 0001857044 us-gaap:PrivatePlacementMember INDP:PurchaseAgreementsMember INDP:IndaptusMember 2021-07-23 0001857044 us-gaap:StockOptionMember 2022-01-01 2022-03-31 0001857044 us-gaap:StockOptionMember 2021-01-01 2021-03-31 0001857044 us-gaap:WarrantMember 2022-01-01 2022-03-31 0001857044 us-gaap:WarrantMember 2021-01-01 2021-03-31 0001857044 us-gaap:PropertyPlantAndEquipmentMember INDP:ComputersAndOtherOfficeEquipmentMember 2021-01-01 2021-12-31 0001857044 us-gaap:PropertyPlantAndEquipmentMember INDP:FurnitureMember 2021-01-01 2021-12-31 0001857044 INDP:PlanTwoThousandTwentyOneMember 2021-06-30 0001857044 srt:ExecutiveOfficerMember 2022-01-25 2022-01-26 0001857044 srt:ExecutiveOfficerMember 2022-01-26 0001857044 INDP:EmployeeMember 2022-01-31 2022-02-01 0001857044 INDP:EmployeeMember 2022-02-01 0001857044 srt:ExecutiveOfficerMember 2022-02-24 2022-02-25 0001857044 srt:ExecutiveOfficerMember 2022-02-25 0001857044 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001857044 us-gaap:ResearchAndDevelopmentExpenseMember 2021-01-01 2021-03-31 0001857044 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001857044 us-gaap:GeneralAndAdministrativeExpenseMember 2021-01-01 2021-03-31 0001857044 INDP:ExercisePriceRangeOneMember 2022-01-01 2022-03-31 0001857044 INDP:ExercisePriceRangeOneMember 2022-03-31 0001857044 INDP:ExercisePriceRangeTwoMember 2022-01-01 2022-03-31 0001857044 INDP:ExercisePriceRangeTwoMember 2022-03-31 0001857044 INDP:ExercisePriceRangeThreeMember 2022-01-01 2022-03-31 0001857044 INDP:ExercisePriceRangeThreeMember 2022-03-31 0001857044 us-gaap:WarrantMember 2022-03-31 0001857044 us-gaap:WarrantMember 2021-12-31 0001857044 us-gaap:WarrantMember 2022-01-01 2022-03-31 0001857044 country:CA INDP:TwoYearLeaseAgreementMember 2021-10-01 0001857044 country:CA INDP:TwoYearLeaseAgreementMember 2021-09-28 2021-10-01 iso4217:USD shares iso4217:USD shares pure utr:sqft 0001857044 false Q1 --12-31 Yes Yes

10-Q true 2022-03-31 2022 false 001-40652 Indaptus Therapeutics, Inc. DE 86-3158720 3 Columbus Circle 15th Floor NY New York 10019 347 480 9760 Common stock, par value $0.01 per share INDP NASDAQ Non-accelerated Filer true false false 8258597

33216311

39132165

2961460

148400

741945

1106653

36919716

40387218

3266

3800

147102

169088

16477

166845

189365

37086561

40576583

3582472

4507676

97185

96465

3679657

4604141

50516

72862

50516

72862

3730173

4677003

0.01

200000000

8258597

82586

52319064

51487881

-19036041

-15670887

-9221

33356388

35899580

37086561

40576583

1297098

489721

2104975

124254

3402073

613975

-3402073

-613975

36919

1554

-3365154

-612421

-0.41

-0.31

8258597

1944672

-3365154

-612421

-9221

-3374375

-612421

835928

8359

1944672

19447

7693994

-7959501

-237701

20445

-612421

835928

8359

1944672

19447

7714439

-8571922

-829677

8258597

82586

51487881

-15670887

35899580

831183

-9221

-3365154

8258597

82586

52319064

-19036041

-9221

33356388

-3365154

-612421

534

213

831183

20445

24155

-364708

109883

-925204

481050

-604988

360

-3117728

-825584

172555

2970681

-2798126

3675000

-5915854

2849416

39132165

1637499

33216311

4486915

800

1318 506

NOTE 1: GENERAL <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">a.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Indaptus Therapeutics, Inc. and its wholly-owned subsidiaries, Decoy Biosystems, Inc. and Intec Pharma Ltd., collectively (the “Company”), is a biotechnology company dedicated to enhancing and expanding curative cancer immunotherapy for patients with unresectable or metastatic solid tumors and lymphomas, which are responsible for more than 90% of all cancer deaths. The Company is developing a novel, multi-targeted product that activates both innate and adaptive anti-tumor and anti-viral immune responses.</td></tr> </table> Indaptus Therapeutics, Inc. (“Indaptus”), formerly “Intec Parent Inc.”, was established and incorporated in Delaware on February 24, 2021, as a private Delaware corporation and wholly-owned subsidiary of Intec Pharma Ltd., (“Intec Israel”), a former publicly traded company. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">b.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">On August 3, 2021, Indaptus completed its merger with Decoy Biosystems, Inc., (“Decoy”), following the satisfaction or waiver of the conditions set forth in the Agreement and Plan of Merger (the “Merger Agreement”), dated as of March 15, 2021 among Indaptus, Decoy, Intec Israel, Domestication Merger Sub Ltd., an Israeli company and a wholly-owned subsidiary of Indaptus (“Domestication Merger Sub”), and Dillon Merger Subsidiary Inc., a Delaware corporation and wholly-owned subsidiary of Indaptus (“the Merger Sub”), pursuant to which Merger Sub merged with and into Decoy, with Decoy surviving as a wholly-owned subsidiary of Indaptus (the “Merger”) and the business conducted by Decoy became the business conducted by Indaptus. Previously, on July 26, 2021, Intec Israel implemented a <span id="xdx_900_eus-gaap--StockholdersEquityReverseStockSplit_c20210725__20210726__us-gaap--SubsidiarySaleOfStockAxis__custom--ShareholdersEquityPostReverseShareSplitMember_zJ1oXT05jzUh" title="Intec Israel, Reverse Share Split Conversion Ratio">1-for-4 reverse share split of its outstanding ordinary shares, options and warrants and proportionate adjustments were made to its exercise prices. In addition, on July 27, 2021, Intec Israel, Indaptus and the Domestication Merger Sub, completed the domestication merger pursuant to the terms and conditions of the Agreement and Plan of Merger and Reorganization, dated April 27, 2021, whereby Domestication Merger Sub merged with and into Intec Israel, with Intec Israel being the surviving entity and a wholly-owned subsidiary of Indaptus.</td></tr> </table> Also, in connection with the Merger, Indaptus changed its name from “Intec Parent, Inc.” to “Indaptus Therapeutics, Inc.”. Following completion of the Merger, shares of Indaptus common stock commenced trading at market open on August 4, 2021, on the Nasdaq Capital Market under the name “Indaptus Therapeutics, Inc.” and under the symbol “INDP”. <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">c.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">In connection with the Merger, on July 23, 2021, Indaptus entered into a securities purchase agreement (the “Purchase Agreement”) with a certain institutional investor, pursuant to which Indaptus agreed to sell and issue, in a private placement (the “Private Placement”), pre-funded warrants and warrants for total net proceeds of approximately $<span id="xdx_900_ecustom--ProceedsFromIssuanceOfPreFundedWarrantsGross_pn5n6_c20210722__20210723__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__dei--LegalEntityAxis__custom--IndaptusMember_z2ktnULUYdgl" title="Total net proceeds from issuance of pre-funded warrants and warrants to purchase Indaptus common stock">27.3 million, after deducting the placement agent’s fees and other estimated offering expenses payable by Indaptus in the amount of approximately $<span id="xdx_90A_ecustom--IssuanceExpenses_pn5n6_c20210722__20210723__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__dei--LegalEntityAxis__custom--IndaptusMember_zhxzAjdjLQD6" title="Issuance expenses">2.7 million. In September 2021, the pre-funded warrant was fully exercised. Each warrant is exercisable at an exercise price of $<span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20210723__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__dei--LegalEntityAxis__custom--IndaptusMember_zY3xo5N6s8f" title="Warrant is exercisable price">11.00 per share and has a term of five and one-half years from the date of issuance. In addition, in connection with the Private Placement, Indaptus issued to the placement agent a warrant to purchase <span id="xdx_903_ecustom--NumberOfWarrantsIssuedToPlacementAgent_iI_c20210723__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__dei--LegalEntityAxis__custom--IndaptusMember_zL3FqGpxPHsl" title="Number of warrants issued to the placement agent">136,364 shares of Indaptus’ common stock at an exercise price of $<span id="xdx_90A_ecustom--ExercisePriceOfWarrantIssuedToPlacementAgent_iI_c20210723__us-gaap--TypeOfArrangementAxis__custom--PurchaseAgreementsMember__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember__dei--LegalEntityAxis__custom--IndaptusMember_zN8BLqNspmQj" title="Exercise price of warrant issued to the placement agent">13.75.</td></tr> </table> Risks and uncertainties The Company is subject to a number of risks similar to those of other companies of similar size in its industry, including, but not limited to, the need for successful development of products, the need for additional capital (or financing) to fund operating losses (see below), competition from substitute products and services from larger companies, protection of proprietary technology, patent litigation, and dependence on key individuals. The COVID-19 pandemic has resulted in significant financial market volatility and uncertainty in the past year. The COVID-19 pandemic is affecting the United States and global economies and may affect the Company’s operations and those of third parties on which the Company relies, including by causing disruptions in the supply of its product candidates and the conduct of future clinical trials. For example, the pandemic has caused our good manufacturing practice (GMP) process to take longer than expected. In addition, the COVID-19 pandemic may affect the operations of the FDA and other health authorities, which could result in delays of reviews and approvals, including with respect to the Company’s product candidates. Additionally, while the potential economic impact brought by, and the duration of, the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce the Company’s ability to access capital, which could negatively impact its short-term and long-term liquidity. The ultimate impact of the COVID-19 pandemic is highly uncertain and subject to change. While it is unknown how long these conditions will last and what the complete financial effect will be to the Company, capital raise efforts and additional development of the Company’s technologies may be negatively affected. Going concern and management’s plans The Company has incurred net losses and utilized cash in operations since inception, has an accumulated deficit as of March 31, 2022, of $19.0 million, and expects to incur future additional losses as clinical testing and commercialization of the Company’s product candidates will require significant additional financing. The Company believes it has adequate cash to fund its operations for at least one year after the date of issuance of these condensed consolidated financial statements. Management plans to raise additional capital through equity and/or debt financings, or other capital sources, including potential collaborations, licenses, and other similar arrangements. However, these plans are not entirely within its control and cannot be assessed as being probable of occurring. The Company’s ability to raise additional capital may be adversely impacted by potential worsening of global economic conditions and the recent disruptions to, and volatility in, financial markets in the United States and worldwide resulting from the developing conflict between Russia and Ukraine and the ongoing COVID-19 pandemic. If the Company is unable to raise capital when needed or on attractive terms, it would be forced to delay, reduce, or eliminate its research and development programs or other operations. If any of these events occur, the Company’s ability to achieve the development and commercialization goals would be adversely affected. These condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.

1-for-4

27300000 2700000

11.00

136364 13.75

-19000000.0

NOTE 2: SIGNIFICANT ACCOUNTING POLICIES Basis of presentation The unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and S-X Article 10 for interim financial statements. Accordingly, they do not contain all information and notes required by US GAAP for annual financial statements. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company’s consolidated financial position as of March 31, 2022, the consolidated results of operations, changes in stockholders’ equity and cash flows for the three-month periods ended March 31, 2022, and 2021. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual financial statements for the year ended December 31, 2021, as filed in the 10-K on March 21, 2022. The condensed consolidated balance sheet data as of December 31, 2021, included in these unaudited condensed consolidated financial statements was derived from the audited financial statements for the year ended December 31, 2021, but does not include all disclosures required by US GAAP for annual financial statements. The results for the three-month period ended March 31, 2022, are not necessarily indicative of the results expected for the year ending December 31, 2022. Principles of consolidation The consolidated financial statements include the accounts of Indaptus and its subsidiaries. Intercompany balances and transactions have been eliminated upon consolidation. Use of estimates The preparation of the unaudited condensed consolidated financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods. The most significant estimates relate to the determination of the fair value of stock-based compensation and the determination of period-end obligations to certain contract research organizations. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. These estimates are based on information available as of the date of the consolidated financial statements; therefore, actual results could differ from those estimates. Loss per share Loss per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of common stock outstanding during the period. Diluted loss per share is based upon the weighted average number of common stock and of common stock equivalents outstanding when dilutive. Common stock equivalents include outstanding stock options and warrants which are included under the treasury stock method when dilutive. <p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zXDin9P55Sd5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The following number of stock options and warrants were excluded from the calculation of diluted loss per share because their effect would have been anti-dilutive for the periods presented (share data): SCHEDULE OF ANTI-DILUTIVE SECURITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220101__20220331_zNeiLsvbETTe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20210101__20210331_zPcrFXLMKAFd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zVZxeMs1jwVa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Outstanding stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,580,623</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">206,079</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zbpzXcwSMag2" style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,090,787</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_z4IrXqglLw1d" style="display: none; vertical-align: bottom; background-color: White"> <td>Anti-dilutive securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,090,787</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> </table> Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of March 31, 2022 and December 31, 2021, cash and cash equivalents consist primarily of checking and money market deposits. The Company’s cash balances exceed those that are federally insured; however, the Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. To date, the Company has not recognized any losses caused by uninsured balances. Marketable securities The Company’s investment in marketable securities included U.S. treasury bonds that are classified as available-for-sale securities pursuant to Accounting Standards Codification (“ASC”) 320 “Investments — Debt Securities”. These investments are recorded at fair value with unrealized gains and losses recorded in Accumulated Other Comprehensive Income (Loss), or AOCI, as a separate component of stockholders’ equity. Property and equipment Property and equipment assets are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The Company uses an estimated useful life of <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20210101__20211231__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersAndOtherOfficeEquipmentMember_z5fbyxGTTlKl" title="Estimated useful life">three years for employee-related computers and other office equipment and <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20210101__20211231__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureMember_zO3NA4nrx83f" title="Estimated useful life">five years for furniture. Leasehold improvements are amortized over the shorter of the lease-term or the estimated useful life of the related asset. Patents The Company expenses patent costs, including related legal costs, as incurred and records such costs within general and administrative expense in the accompanying consolidated statements of operations. Research and development expenses Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including clinical trials and professional services. All costs associated with research and developments are expensed as incurred. The Company accrues for expenses resulting from obligations under agreements with contract research organizations (“CROs”), contract manufacturing organizations (“CMOs”), and other outside service providers for which payment flows do not match the periods over which services or materials are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements with CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. In the event advance payments are made to a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset, which will be amortized or expensed as the contracted services are performed. Income taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded for deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will not be realized in the foreseeable future. As of March 31, 2022 and December 31, 2021, the Company has recorded a full valuation allowance against its deferred tax assets. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expenses. Stock-based compensation The Company measures and records the expense related to stock-based payment awards based on the fair value of those awards as determined using the Black-Scholes-Merton (“Black-Scholes”) option pricing model as of the date of grant. The Company recognizes stock-based compensation expense over the requisite service period of the individual grant, generally equal to the vesting period, on a straight-line basis. The Black-Scholes model requires the use of highly subjective and complex assumptions, which determine the fair value of stock-based awards, including the option’s expected term and the price volatility of the underlying stock. The Company estimates the fair value of options granted by using the Black-Scholes model with the following assumptions: Expected Volatility—The Company estimated volatility for option grants by evaluating the historical volatility of a peer group of companies for the period immediately preceding the option grant for a term that is approximately equal to the options’ expected term. Expected Term—The expected term of the Company’s options represents the period that the stock-based awards are expected to be outstanding. The expected term was estimated using the simplified method for employee stock options since the Company does not have adequate historical exercise data to estimate the expected term. Risk-Free Interest Rate—The risk-free interest rate is based on the implied yield currently available on US Treasury zero-coupon issues with a term that is equal to the options’ expected term at the grant date. Dividend Yield—The Company has not declared or paid dividends to date and does not anticipate declaring dividends. As such, the dividend yield has been estimated to be zero. The Company has elected to recognize forfeitures as they occur. Fair value measurements Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company follows the established framework for measuring fair value and providing disclosures about fair value measurements. The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">Level 1:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Quoted prices in active markets for identical assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">Level 2:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">Level 3:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</td></tr> </table> ASC 820, Fair Value Measurement, requires all entities to disclose the fair value of financial instruments, both assets and liabilities, for which it is practicable to estimate fair value, and defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of March 31, 2022 and December 31, 2021, the recorded values of cash and cash equivalents, marketable securities, assets held for sale, prepaid expenses, and accounts payable and other current liabilities approximate their fair values due to the short-term nature of these items.

Basis of presentation The unaudited interim condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and S-X Article 10 for interim financial statements. Accordingly, they do not contain all information and notes required by US GAAP for annual financial statements. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company’s consolidated financial position as of March 31, 2022, the consolidated results of operations, changes in stockholders’ equity and cash flows for the three-month periods ended March 31, 2022, and 2021. These unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in the Company’s annual financial statements for the year ended December 31, 2021, as filed in the 10-K on March 21, 2022. The condensed consolidated balance sheet data as of December 31, 2021, included in these unaudited condensed consolidated financial statements was derived from the audited financial statements for the year ended December 31, 2021, but does not include all disclosures required by US GAAP for annual financial statements. The results for the three-month period ended March 31, 2022, are not necessarily indicative of the results expected for the year ending December 31, 2022.

Principles of consolidation The consolidated financial statements include the accounts of Indaptus and its subsidiaries. Intercompany balances and transactions have been eliminated upon consolidation.

Use of estimates The preparation of the unaudited condensed consolidated financial statements in accordance with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting periods. The most significant estimates relate to the determination of the fair value of stock-based compensation and the determination of period-end obligations to certain contract research organizations. Management evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors, including the current economic environment, and makes adjustments when facts and circumstances dictate. These estimates are based on information available as of the date of the consolidated financial statements; therefore, actual results could differ from those estimates.

Loss per share Loss per share, basic and diluted, is computed on the basis of the net loss for the period divided by the weighted average number of common stock outstanding during the period. Diluted loss per share is based upon the weighted average number of common stock and of common stock equivalents outstanding when dilutive. Common stock equivalents include outstanding stock options and warrants which are included under the treasury stock method when dilutive. <p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zXDin9P55Sd5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The following number of stock options and warrants were excluded from the calculation of diluted loss per share because their effect would have been anti-dilutive for the periods presented (share data): SCHEDULE OF ANTI-DILUTIVE SECURITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220101__20220331_zNeiLsvbETTe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20210101__20210331_zPcrFXLMKAFd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zVZxeMs1jwVa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Outstanding stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,580,623</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">206,079</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zbpzXcwSMag2" style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,090,787</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_z4IrXqglLw1d" style="display: none; vertical-align: bottom; background-color: White"> <td>Anti-dilutive securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,090,787</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> </table>

<p id="xdx_896_eus-gaap--ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_zXDin9P55Sd5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The following number of stock options and warrants were excluded from the calculation of diluted loss per share because their effect would have been anti-dilutive for the periods presented (share data): SCHEDULE OF ANTI-DILUTIVE SECURITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49F_20220101__20220331_zNeiLsvbETTe" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_491_20210101__20210331_zPcrFXLMKAFd" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">For the three months ended March 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_403_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--StockOptionMember_zVZxeMs1jwVa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Outstanding stock options</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">1,580,623</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">206,079</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_hus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis__us-gaap--WarrantMember_zbpzXcwSMag2" style="vertical-align: bottom; background-color: White"> <td>Warrants</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,090,787</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_z4IrXqglLw1d" style="display: none; vertical-align: bottom; background-color: White"> <td>Anti-dilutive securities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,090,787</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> </table>

1580623

206079

3090787

Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be cash equivalents. As of March 31, 2022 and December 31, 2021, cash and cash equivalents consist primarily of checking and money market deposits. The Company’s cash balances exceed those that are federally insured; however, the Company believes it is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash and cash equivalents are held. To date, the Company has not recognized any losses caused by uninsured balances.

Marketable securities The Company’s investment in marketable securities included U.S. treasury bonds that are classified as available-for-sale securities pursuant to Accounting Standards Codification (“ASC”) 320 “Investments — Debt Securities”. These investments are recorded at fair value with unrealized gains and losses recorded in Accumulated Other Comprehensive Income (Loss), or AOCI, as a separate component of stockholders’ equity.

Property and equipment Property and equipment assets are stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets. The Company uses an estimated useful life of <span id="xdx_90B_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20210101__20211231__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputersAndOtherOfficeEquipmentMember_z5fbyxGTTlKl" title="Estimated useful life">three years for employee-related computers and other office equipment and <span id="xdx_907_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dt_c20210101__20211231__us-gaap--FairValueByAssetClassAxis__us-gaap--PropertyPlantAndEquipmentMember__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--FurnitureMember_zO3NA4nrx83f" title="Estimated useful life">five years for furniture. Leasehold improvements are amortized over the shorter of the lease-term or the estimated useful life of the related asset.

P3Y

P5Y

Patents The Company expenses patent costs, including related legal costs, as incurred and records such costs within general and administrative expense in the accompanying consolidated statements of operations. Research and development expenses Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, subcontractors and materials used for research and development activities, including clinical trials and professional services. All costs associated with research and developments are expensed as incurred. The Company accrues for expenses resulting from obligations under agreements with contract research organizations (“CROs”), contract manufacturing organizations (“CMOs”), and other outside service providers for which payment flows do not match the periods over which services or materials are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements with CROs, CMOs, and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through analysis with internal personnel and external service providers as to the progress or stage of completion of the services. In the event advance payments are made to a CRO, CMO, or outside service provider, the payments will be recorded as a prepaid asset, which will be amortized or expensed as the contracted services are performed.

Income taxes Income taxes are accounted for under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recorded for deferred tax assets if it is more likely than not that some portion or all of the deferred tax assets will not be realized in the foreseeable future. As of March 31, 2022 and December 31, 2021, the Company has recorded a full valuation allowance against its deferred tax assets. The Company recognizes the effect of income tax positions only if those positions are more likely than not of being sustained. Recognized income tax positions are measured at the largest amount that is greater than 50% likely of being realized. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. The Company records interest related to unrecognized tax benefits in interest expense and penalties in general and administrative expenses.

Stock-based compensation The Company measures and records the expense related to stock-based payment awards based on the fair value of those awards as determined using the Black-Scholes-Merton (“Black-Scholes”) option pricing model as of the date of grant. The Company recognizes stock-based compensation expense over the requisite service period of the individual grant, generally equal to the vesting period, on a straight-line basis. The Black-Scholes model requires the use of highly subjective and complex assumptions, which determine the fair value of stock-based awards, including the option’s expected term and the price volatility of the underlying stock. The Company estimates the fair value of options granted by using the Black-Scholes model with the following assumptions: Expected Volatility—The Company estimated volatility for option grants by evaluating the historical volatility of a peer group of companies for the period immediately preceding the option grant for a term that is approximately equal to the options’ expected term. Expected Term—The expected term of the Company’s options represents the period that the stock-based awards are expected to be outstanding. The expected term was estimated using the simplified method for employee stock options since the Company does not have adequate historical exercise data to estimate the expected term. Risk-Free Interest Rate—The risk-free interest rate is based on the implied yield currently available on US Treasury zero-coupon issues with a term that is equal to the options’ expected term at the grant date. Dividend Yield—The Company has not declared or paid dividends to date and does not anticipate declaring dividends. As such, the dividend yield has been estimated to be zero. The Company has elected to recognize forfeitures as they occur.

Fair value measurements Fair value is defined as the exchange price that would be received for an asset or an exit price that would be paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The Company follows the established framework for measuring fair value and providing disclosures about fair value measurements. The accounting guidance classifies fair value measurements in one of the following three categories for disclosure purposes: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.75in">Level 1:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Quoted prices in active markets for identical assets or liabilities.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">Level 2:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Inputs other than Level 1 prices for similar assets or liabilities that are directly or indirectly observable in the marketplace.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif">Level 3:</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Unobservable inputs which are supported by little or no market activity and values determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant judgment or estimation.</td></tr> </table> ASC 820, Fair Value Measurement, requires all entities to disclose the fair value of financial instruments, both assets and liabilities, for which it is practicable to estimate fair value, and defines the fair value of a financial instrument as the amount at which the instrument could be exchanged in a current transaction between willing parties. As of March 31, 2022 and December 31, 2021, the recorded values of cash and cash equivalents, marketable securities, assets held for sale, prepaid expenses, and accounts payable and other current liabilities approximate their fair values due to the short-term nature of these items.

NOTE 3: MARKETABLE SECURITIES The Company’s investment in marketable securities included U.S. treasury bonds with maturities of less than one year. These investments are classified as available-for-sale and are recorded at fair value with unrealized gains and losses recorded in AOCI. These investments are categorized as Level 2. As of March 31, 2022, the amount of the marketable securities is $2,961,460. As of December 31, 2021, the Company had no marketable securities. The unrealized losses for the three-month period ended March 31, 2022 amounted to $9,221.

2961460

9221

NOTE 4: PREPAID EXPENSES AND OTHER CURRENT ASSETS Prepaid expenses and other current assets are comprised of the following: SCHEDULE OF PREPAID EXPENSE AND OTHER CURRENT ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_490_20220331_zkbLO7UfSkDl" style="text-align: center">March 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_49B_20211231_zBovY2NLh6M6" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_408_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAz50c_zPxtnlcUKO12" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Prepaid insurance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">543,986</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">945,023</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--PrepaidResearchAndDevelopment_iI_pp0p0_maPEAOAz50c_z2Zqh01NesS2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">78,353</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">127,643</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OtherReceivables_iI_pp0p0_maPEAOAz50c_zipoe2SwTp0a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,056</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPEAOAz50c_zjkRmNgN1nYg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Other prepaid expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">119,606</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,931</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAz50c_zJE3uE0aIE72" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">741,945</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,106,653</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> Prepaid expenses and other current assets are comprised of the following: SCHEDULE OF PREPAID EXPENSE AND OTHER CURRENT ASSETS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2" id="xdx_490_20220331_zkbLO7UfSkDl" style="text-align: center">March 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_49B_20211231_zBovY2NLh6M6" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_408_eus-gaap--PrepaidInsurance_iI_pp0p0_maPEAOAz50c_zPxtnlcUKO12" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Prepaid insurance</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">543,986</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">945,023</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_408_ecustom--PrepaidResearchAndDevelopment_iI_pp0p0_maPEAOAz50c_z2Zqh01NesS2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Prepaid research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">78,353</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">127,643</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--OtherReceivables_iI_pp0p0_maPEAOAz50c_zipoe2SwTp0a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Other receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,056</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OtherPrepaidExpenseCurrent_iI_pp0p0_maPEAOAz50c_zjkRmNgN1nYg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Other prepaid expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">119,606</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,931</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--PrepaidExpenseAndOtherAssetsCurrent_iTI_pp0p0_mtPEAOAz50c_zJE3uE0aIE72" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total prepaid expenses and other current assets</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">741,945</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">1,106,653</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

543986

945023

78353 127643

21056

119606

12931

741945

1106653

NOTE 5: ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES <p id="xdx_89A_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z6fFpxjnXyzh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Accounts payable and other current liabilities are comprised of the following: SCHEDULE OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" id="xdx_496_20220331_zEPZPeStSvRb" style="text-align: center">March 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_492_20211231_zLFo41D0Ef2d" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40D_eus-gaap--AccountsPayableCurrent_iI_pp0p0_maAPAOAzxRP_zIZR2676I47f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,834,683</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,637,806</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0p0_maAPAOAzxRP_z5126bsEl7x9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued employee costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">276,285</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,371,136</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maAPAOAzxRP_z8vBhvq4RIxg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">71,186</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">139,871</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--AccruedResearchAndDevelopmentCurrent_iI_pp0p0_maAPAOAzxRP_zkEHViWY6LKe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">175,978</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">135,751</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--AccruedBoardFeesCurrent_iI_pp0p0_maAPAOAzxRP_zZy9cXlskkTi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued board fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">116,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">125,333</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DelawareFranchiseTaxesPayableCurrent_iI_pp0p0_maAPAOAzxRP_z69uLcZgy7wd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Delaware franchise taxes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maAPAOAzxRP_zF3mlTNvu1ag" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Other accrued expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,340</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">97,778</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pp0p0_mtAPAOAzxRP_zSGttkuu1eSj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total accounts payable and other current liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,582,472</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,507,676</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

<p id="xdx_89A_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_z6fFpxjnXyzh" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Accounts payable and other current liabilities are comprised of the following: SCHEDULE OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td> </td> <td colspan="2" id="xdx_496_20220331_zEPZPeStSvRb" style="text-align: center">March 31,</td><td> </td><td> </td> <td colspan="2" id="xdx_492_20211231_zLFo41D0Ef2d" style="text-align: center">December 31,</td><td> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: right"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40D_eus-gaap--AccountsPayableCurrent_iI_pp0p0_maAPAOAzxRP_zIZR2676I47f" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Accounts payable</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,834,683</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,637,806</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--EmployeeRelatedLiabilitiesCurrent_iI_pp0p0_maAPAOAzxRP_z5126bsEl7x9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued employee costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">276,285</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,371,136</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AccruedProfessionalFeesCurrent_iI_pp0p0_maAPAOAzxRP_z8vBhvq4RIxg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued professional fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">71,186</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">139,871</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--AccruedResearchAndDevelopmentCurrent_iI_pp0p0_maAPAOAzxRP_zkEHViWY6LKe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Accrued research and development</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">175,978</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">135,751</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_ecustom--AccruedBoardFeesCurrent_iI_pp0p0_maAPAOAzxRP_zZy9cXlskkTi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Accrued board fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">116,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">125,333</td><td style="text-align: left"> </td></tr> <tr id="xdx_40F_ecustom--DelawareFranchiseTaxesPayableCurrent_iI_pp0p0_maAPAOAzxRP_z69uLcZgy7wd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Delaware franchise taxes payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">50,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_pp0p0_maAPAOAzxRP_zF3mlTNvu1ag" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Other accrued expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">58,340</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">97,778</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--AccountsPayableAndOtherAccruedLiabilitiesCurrent_iTI_pp0p0_mtAPAOAzxRP_zSGttkuu1eSj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total accounts payable and other current liabilities</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,582,472</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">4,507,676</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2834683

2637806

276285

1371136

71186

139871

175978 135751 116000 125333 50000

58340

97778

3582472

4507676

<p id="xdx_803_eus-gaap--DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_zsUhjBSbH2v5" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">NOTE 6: STOCK-BASED COMPENSATION In June 2021, the Intec Israel shareholders voted to approve the Indaptus 2021 Stock Incentive Plan, an equity incentive plan for grants to employees, officers, consultants, directors and other service providers, (the “2021 Plan”), that became effective upon the closing of the Merger. The 2021 Plan provides for up to <span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_iI_pid_c20210630__us-gaap--PlanNameAxis__custom--PlanTwoThousandTwentyOneMember_zhnLm0ih94pd" title="Share based Compensation arrangement by share based payment award, number of shares available for grant">1,864,963 shares of the Company’s common stock. The 2021 Plan provides for the grant of non-qualified stock options, incentive stock options, restricted stock awards, restricted stock units, unrestricted stock awards, stock appreciation rights and other forms of stock-based compensation. The 2021 Plan permits the Company’s board to change the type, terms and conditions of awards as circumstances may change. This flexibility to adjust the type of compensation to be granted is particularly important given current economic and world events. On January 26, 2022, Indaptus’ board of directors approved grant of options to purchase <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220125__20220126__srt--TitleOfIndividualAxis__srt--ExecutiveOfficerMember_zPH0j8SDnvuh" title="Options granted to purchase of shares">289,200 shares of common stock to executives. The options are exercisable at $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220126__srt--TitleOfIndividualAxis__srt--ExecutiveOfficerMember_zh7cv4zN9WOc" title="Options exercisable price">4.90 per share, vest over three years, and expire <span id="xdx_90E_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dt_c20220125__20220126__srt--TitleOfIndividualAxis__srt--ExecutiveOfficerMember_zplxQXwrMW63" title="Options expiration period">ten years after grant. On February 1, 2022, Indaptus’ board of directors approved a grant of options to purchase <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220131__20220201__srt--TitleOfIndividualAxis__custom--EmployeeMember_zgcvbnXHhgX3" title="Options granted to purchase of shares">90,000 shares of common stock to a new employee. The options are exercisable at $<span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220201__srt--TitleOfIndividualAxis__custom--EmployeeMember_zTBEgC8Vyo86" title="Options exercisable price">4.97 per share, vest over three years, and expire <span id="xdx_903_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dt_c20220131__20220201__srt--TitleOfIndividualAxis__custom--EmployeeMember_zJpZrDiWyeV4" title="Options expiration period">ten years after grant. On February 25, 2022, Indaptus’ board of directors approved a grant of options to purchase <span id="xdx_90A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20220224__20220225__srt--TitleOfIndividualAxis__srt--ExecutiveOfficerMember_zqNTAycjR9J" title="Options granted to purchase of shares">60,000 shares of common stock to an executive. The options are exercisable at $<span id="xdx_907_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iI_c20220225__srt--TitleOfIndividualAxis__srt--ExecutiveOfficerMember_zktCZP3ypWZd" title="Options exercisable price">4.18 per share, vest over three years, and expire <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_c20220224__20220225__srt--TitleOfIndividualAxis__srt--ExecutiveOfficerMember_zxlITfB8iZ15" title="Options expiration period">ten years after grant. <p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zSSSOLgP6ZZ6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">A summary of the stock option activity during the three months ended March 31, 2022, is presented in the table below: SCHEDULE OF SHARE BASED COMPENSATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted average</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of options</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Remaining contractual life (in years)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Intrinsic value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding as of January 1, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220331_zqHN1ezWa0Xd" style="width: 11%; text-align: right" title="Outstanding at beginning of the period">1,174,600</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220331_zdukapKXqvu2" title="Outstanding at beginning of the period, Exercise price">17.10</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20220331_z2rt9tLWSmUg" title="Outstanding at beginning of the period, Weighted average remaining contractual life">9.1</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20220331_ztZ4J4MPp31e" style="width: 11%; text-align: right" title="Outstanding at beginning of the period, Intrinsic value">241,103</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20220331_zKV5FJe67QRh" style="text-align: right" title="Granted">439,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4.82</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220101__20220331_zeS6Xw6qeWi" title="Granted, Weighted average remaining contractual life">9.8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20220331_zVB7mkEfWZA6" style="text-align: right" title="Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Forfeited and cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20220101__20220331_zirW9vqg02m8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forfeited and cancelled">(33,237</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20220331_zwm2LJviCxQa" title="Forfeited and cancelled, exercise price">11.46</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedAndCancelledWeightedAverageRemainingContractualTerm_dtY_c20220101__20220331_zfpHfFoVVKjk" title="Forfeited and Cancelled, Weighted average remaining contractual life">9.3</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding as of March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20220331_zDaPL0dCjt4c" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding at end of period">1,580,623</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220331_ztvtQ90eaGp6" title="Outstanding at end of period, Exercise price">13.80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331_zFNucBTojuc5" title="Outstanding at end of period, Weighted average remaining contractual life">9.2</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20220101__20220331_zC8O7VTUrnYf" style="padding-bottom: 2.5pt; text-align: right" title="Outstanding at end of period, intrinsic value">96,870</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable as of March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20220331_zRY9BzZ9GaUj" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable at end of period">127,749</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20220331_zeQ7GUnfswgk" title="Exercisable at end of period, Exercise price">81.20</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331_z66wwoQlrXF9" title="Exercisable at end of period, Weighted average remaining contractual life">6.3</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20220101__20220331_zMSPCzWZJQF5" style="padding-bottom: 2.5pt; text-align: right" title="Exercisable at end of period, intrinsic value">96,870</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and expected to vest March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20220101__20220331_zlezF37Fv3zl" style="border-bottom: Black 2.5pt double; text-align: right" title="Vested and expected to vest">1,580,623</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220331_zL5Dz5RWxcfi" title="Vested and expected to vest, Exercise price">13.80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331_zq4DovEw4qRi" title="Vested and expected to vest, Weighted average remaining contractual life">9.2</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20220101__20220331_z2DSwsyDnMic" style="padding-bottom: 2.5pt; text-align: right" title="Vested and expected to vest, intrinsic value">96,870</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company recognized stock-based compensation expense of $831,183 and $20,445 during the three months ended March 31, 2022 and 2021, respectively. The following table summarizes the total stock-based compensation expense included in the condensed consolidated statements of operations for the periods presented: SCHEDULE OF STOCK BASED COMPENSATION EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220101__20220331_zssKI1bSs7rj" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20210101__20210331_zlaSaD7ZCFEa" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the three months ended March 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zGaY5Jxt5ipi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">170,163</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8,189</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zgNI6XOXQY14" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">661,020</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,256</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ShareBasedCompensation_zhWEPX2c6ONf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">831,183</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">20,445</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> As of March 31, 2022, total compensation cost not yet recognized related to unvested stock options was approximately $<span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_pn5n6_c20220331_zZGHAAMPewF5" title="Compensation cost not yet recognized related to unvested stock options">6.7 million, which is expected to be recognized over a weighted-average period of <span id="xdx_90C_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20220331_zV69JBjFNLhe" title="Weighted-average period over which unrecognized compensation expense is expected to be recognized">2.3 years. The Company estimates the fair value of stock options on the date of grant using the Black-Scholes option-pricing model. The Black-Scholes option-pricing model requires estimates of highly subjective assumptions, which affect the fair value of each stock option. The weighted average inputs used to measure the value of the options granted during the three months ended March 31, 2022 are presented in the table below. The weighted average fair value of stock options issued during the three months ended March 31, 2022 was $3.89 per share. <p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zgUmbmqPtVLl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">SCHEDULE OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Stock price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--SharePrice_iI_c20220331_zI8Mcijwe27j" style="width: 18%; text-align: right" title="Stock Price">4.82</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20220331_zpY0EdK9mjVj" style="text-align: right" title="Exercise price">4.82</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.9</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220331_zqQvm5Hpy3k" style="text-align: right" title="Volatility rate">105.5</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk free rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220331_z1WH0pN7AgAl" style="text-align: right" title="Risk free rate">1.7</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220331_z6jUU8NP1uB2" style="text-align: right" title="Dividend yield">0.0</td><td style="text-align: left">%</td></tr> </table> The following table presents the exercise price of outstanding stock options as of March 31, 2022: <p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zs6ReK7SQ4K6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt">Exercise price</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Options outstanding</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">$<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zmzpDBg6Dmr9" title="Exercise price range lower range limit">0.01 - $<span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zrcwjQEOFAWj" title="Exercise price range upper range limit">8.00</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zGXhJyqstSZi" style="width: 18%; text-align: right" title="Outstanding options, number of outstanding options at the end of period">539,925</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>$<span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zNTHdN2EpNt8" title="Exercise price range lower range limit">8.01 - $<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zZRDuV7tBfa3" title="Exercise price range upper range limit">16.00</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zP9v9gP28cgi" style="text-align: right" title="Outstanding options, number of outstanding options at the end of period">1,006,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">$<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zLE84VfbEqm6" title="Exercise price range lower range limit">16.00 or higher</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z3XhuxriC2eb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Outstanding options, number of outstanding options at the end of period">34,698</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331_z27z0qL0CZv8" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding options, number of outstanding options at the end of period">1,580,623</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1864963

289200

4.90

P10Y

90000

4.97

P10Y

60000

4.18

P10Y

<p id="xdx_89C_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zSSSOLgP6ZZ6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">A summary of the stock option activity during the three months ended March 31, 2022, is presented in the table below: SCHEDULE OF SHARE BASED COMPENSATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">Weighted average</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: center"> </td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Number of options</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Exercise price</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Remaining contractual life (in years)</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Intrinsic value</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 40%">Outstanding as of January 1, 2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_c20220101__20220331_zqHN1ezWa0Xd" style="width: 11%; text-align: right" title="Outstanding at beginning of the period">1,174,600</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 11%; text-align: right"><span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_c20220101__20220331_zdukapKXqvu2" title="Outstanding at beginning of the period, Exercise price">17.10</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 11%; text-align: right"><span id="xdx_902_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm_dtY_c20220101__20220331_z2rt9tLWSmUg" title="Outstanding at beginning of the period, Weighted average remaining contractual life">9.1</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_98C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_pp0p0_c20220101__20220331_ztZ4J4MPp31e" style="width: 11%; text-align: right" title="Outstanding at beginning of the period, Intrinsic value">241,103</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Granted</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_c20220101__20220331_zKV5FJe67QRh" style="text-align: right" title="Granted">439,200</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">4.82</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_909_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm_dtY_c20220101__20220331_zeS6Xw6qeWi" title="Granted, Weighted average remaining contractual life">9.8</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt">Exercised</td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--StockIssuedDuringPeriodSharesStockOptionsExercised_pid_c20220101__20220331_zVB7mkEfWZA6" style="text-align: right" title="Exercised">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Forfeited and cancelled</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_98A_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_pid_di_c20220101__20220331_zirW9vqg02m8" style="border-bottom: Black 1.5pt solid; text-align: right" title="Forfeited and cancelled">(33,237</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_c20220101__20220331_zwm2LJviCxQa" title="Forfeited and cancelled, exercise price">11.46</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt; text-align: right"><span id="xdx_90D_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedAndCancelledWeightedAverageRemainingContractualTerm_dtY_c20220101__20220331_zfpHfFoVVKjk" title="Forfeited and Cancelled, Weighted average remaining contractual life">9.3</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt; text-align: left">$</td><td style="padding-bottom: 1.5pt; text-align: right">-</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 2.5pt">Outstanding as of March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_pid_c20220101__20220331_zDaPL0dCjt4c" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding at end of period">1,580,623</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_905_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220331_ztvtQ90eaGp6" title="Outstanding at end of period, Exercise price">13.80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20220101__20220331_zFNucBTojuc5" title="Outstanding at end of period, Weighted average remaining contractual life">9.2</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_983_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_pp0p0_c20220101__20220331_zC8O7VTUrnYf" style="padding-bottom: 2.5pt; text-align: right" title="Outstanding at end of period, intrinsic value">96,870</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Exercisable as of March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20220101__20220331_zRY9BzZ9GaUj" style="border-bottom: Black 2.5pt double; text-align: right" title="Exercisable at end of period">127,749</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20220101__20220331_zeQ7GUnfswgk" title="Exercisable at end of period, Exercise price">81.20</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90B_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331_z66wwoQlrXF9" title="Exercisable at end of period, Weighted average remaining contractual life">6.3</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_982_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_pp0p0_c20220101__20220331_zMSPCzWZJQF5" style="padding-bottom: 2.5pt; text-align: right" title="Exercisable at end of period, intrinsic value">96,870</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Vested and expected to vest March 31, 2022</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_iE_c20220101__20220331_zlezF37Fv3zl" style="border-bottom: Black 2.5pt double; text-align: right" title="Vested and expected to vest">1,580,623</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_iE_pid_c20220101__20220331_zL5Dz5RWxcfi" title="Vested and expected to vest, Exercise price">13.80</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt; text-align: right"><span id="xdx_905_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331_zq4DovEw4qRi" title="Vested and expected to vest, Weighted average remaining contractual life">9.2</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="padding-bottom: 2.5pt; text-align: left">$</td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_pp0p0_c20220101__20220331_z2DSwsyDnMic" style="padding-bottom: 2.5pt; text-align: right" title="Vested and expected to vest, intrinsic value">96,870</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

1174600

17.10

P9Y1M6D

241103

439200

4.82

P9Y9M18D

33237

11.46

P9Y3M18D

1580623

13.80

P9Y2M12D

96870

127749

81.20

P6Y3M18D

96870

1580623

13.80

P9Y2M12D

96870

831183

20445

SCHEDULE OF STOCK BASED COMPENSATION EXPENSES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20220101__20220331_zssKI1bSs7rj" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_495_20210101__20210331_zlaSaD7ZCFEa" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; text-align: center">For the three months ended March 31,</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2021</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--ResearchAndDevelopmentExpenseMember_zGaY5Jxt5ipi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Research and development</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">170,163</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">8,189</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--ShareBasedCompensation_hus-gaap--IncomeStatementLocationAxis__us-gaap--GeneralAndAdministrativeExpenseMember_zgNI6XOXQY14" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">General and administrative</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">661,020</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">12,256</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--ShareBasedCompensation_zhWEPX2c6ONf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total stock-based compensation expense</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">831,183</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">20,445</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

170163

8189

661020

12256

831183

20445

6700000

P2Y3M18D

3.89

<p id="xdx_890_eus-gaap--ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_zgUmbmqPtVLl" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">SCHEDULE OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">2022</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">Stock price</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td id="xdx_987_eus-gaap--SharePrice_iI_c20220331_zI8Mcijwe27j" style="width: 18%; text-align: right" title="Stock Price">4.82</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercise price</td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_c20220331_zpY0EdK9mjVj" style="text-align: right" title="Exercise price">4.82</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Expected term (in years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5.9</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Volatility</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_pid_dp_uPure_c20220101__20220331_zqQvm5Hpy3k" style="text-align: right" title="Volatility rate">105.5</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Risk free rate</td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_pid_dp_uPure_c20220101__20220331_z1WH0pN7AgAl" style="text-align: right" title="Risk free rate">1.7</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Dividend yield</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_pid_dp_uPure_c20220101__20220331_z6jUU8NP1uB2" style="text-align: right" title="Dividend yield">0.0</td><td style="text-align: left">%</td></tr> </table>

4.82

P5Y10M24D

1.055

0.017

0.000

<p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_zs6ReK7SQ4K6" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt">Exercise price</td><td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; text-align: center">Options outstanding</td><td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%">$<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zmzpDBg6Dmr9" title="Exercise price range lower range limit">0.01 - $<span id="xdx_900_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zrcwjQEOFAWj" title="Exercise price range upper range limit">8.00</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeOneMember_zGXhJyqstSZi" style="width: 18%; text-align: right" title="Outstanding options, number of outstanding options at the end of period">539,925</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>$<span id="xdx_90E_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zNTHdN2EpNt8" title="Exercise price range lower range limit">8.01 - $<span id="xdx_909_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zZRDuV7tBfa3" title="Exercise price range upper range limit">16.00</td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeTwoMember_zP9v9gP28cgi" style="text-align: right" title="Outstanding options, number of outstanding options at the end of period">1,006,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">$<span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_zLE84VfbEqm6" title="Exercise price range lower range limit">16.00 or higher</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceRangeThreeMember_z3XhuxriC2eb" style="border-bottom: Black 1.5pt solid; text-align: right" title="Outstanding options, number of outstanding options at the end of period">34,698</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt">Total</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_iI_c20220331_z27z0qL0CZv8" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding options, number of outstanding options at the end of period">1,580,623</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

0.01

8.00

539925

8.01

16.00

1006000

16.00

34698

1580623

NOTE 7: CAPITALIZATION <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">a.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As of March 31, 2022 and December 31, 2021, the Company had 200,000,000 shares of common stock authorized and 8,258,597 shares of common stock issued and outstanding.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">b.</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As of March 31, 2022 and December 31, 2021, there were warrants outstanding to purchase an aggregate of <span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zWjGRYzLUDd7" title="Warrant outstanding"><span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iI_c20211231__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zJAgRw1J4TAi" title="Warrant outstanding">3,090,787 shares of common stock of Indaptus. As of March 31, 2022, these warrants are exercisable at a weighted average price of $<span id="xdx_904_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iI_c20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zSRpkOwKf5C" title="Weighted average exercise price">12.50 and their weighted average remaining contractual term is <span id="xdx_908_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_dtY_c20220101__20220331__us-gaap--StatementEquityComponentsAxis__us-gaap--WarrantMember_zOy7xPK8Jhli" title="Weighted average, remaining contractual life">4.7 years.</td></tr> </table>

200000000

8258597

3090787

12.50

P4Y8M12D

NOTE 8: COMMITMENTS AND CONTINGENCIES Litigation As of the date of issuance of these consolidated financial statements there were no pending legal proceedings against the Company that are expected to have a material adverse effect on cash flows, financial condition or results of operations. From time to time, the Company could become involved in disputes and various litigation matters that arise in the normal course of business. These may include disputes and lawsuits related to intellectual property, licensing, contract law and employee relations matters. Periodically, the Company reviews the status of significant matters, if any exist, and assesses its potential financial exposure. If the potential loss from any claim or legal claim is considered probable and the amount can be estimated, the Company accrues a liability for the estimated loss. Legal proceedings are subject to uncertainties, and the outcomes are difficult to predict. Because of such uncertainties, accruals are based on the best information available at the time. As additional information becomes available, the Company reassesses the potential liability related to pending claims and litigation. Leases On October 1, 2021, the Company entered into a noncancelable two-year operating lease agreement for approximately 2,000 square feet of office space in San Diego, California. The base rent is $<span id="xdx_90D_eus-gaap--LeaseAndRentalExpense_c20210928__20211001__srt--StatementGeographicalAxis__country--CA__us-gaap--TypeOfArrangementAxis__custom--TwoYearLeaseAgreementMember_zW6pkjNVyOw4" title="Base rent">7,999 per month with an increase of <span id="xdx_901_ecustom--RateOfIncreaseInLeaseRent_pid_dp_uPure_c20210928__20211001__srt--StatementGeographicalAxis__country--CA__us-gaap--TypeOfArrangementAxis__custom--TwoYearLeaseAgreementMember_zkPSgX9g5wD8" title="Rate of increase in lease rent">3% after the first anniversary of the lease term commencement, which was November 1, 2021. The lease liability is measured at a discount rate of <span id="xdx_90C_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_pid_dp_uPure_c20211001__srt--StatementGeographicalAxis__country--CA__us-gaap--TypeOfArrangementAxis__custom--TwoYearLeaseAgreementMember_zdr7X1qESv91" title="Lease liability discount rate">7%. Future minimum annual lease payments under the Company’s noncancelable operating lease as of March 31, 2022 are as follows: SUMMARY OF MINIMUM LEASE PAYMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_49D_20220331_zAjFHus8p7Fl" style="border-bottom: Black 1.5pt solid; text-align: right">2022</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPznB5_zk2Fh1TnfWZ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">72,469</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_iI_maLOLLPznB5_zU9GAvge925k" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">82,387</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPznB5_zVWqHMGW2cOc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total minimum lease payments</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">154,856</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zMzJlRRvn2Z" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,155</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zZwAlhsGEZwj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Present value of operating lease liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">147,701</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_z2VFP9dkux7b" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(97,185</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_z6skcjW23Np4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liability, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">50,516</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company recognized rent expense of $26,542 and $6,365 during the three months ended March 31, 2022 and 2021, respectively. Total cash payments for the operating lease totaled $26,182 and $6,365 during the three months ended March 31, 2022 and 2021, respectively.

2000

7999

0.03

0.07

Future minimum annual lease payments under the Company’s noncancelable operating lease as of March 31, 2022 are as follows: SUMMARY OF MINIMUM LEASE PAYMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td id="xdx_49D_20220331_zAjFHus8p7Fl" style="border-bottom: Black 1.5pt solid; text-align: right">2022</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maLOLLPznB5_zk2Fh1TnfWZ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 78%; text-align: left">2022</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 18%; text-align: right">72,469</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_iI_maLOLLPznB5_zU9GAvge925k" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">2023</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">82,387</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtLOLLPznB5_zVWqHMGW2cOc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Total minimum lease payments</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">154,856</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_zMzJlRRvn2Z" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: amount representing interest</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(7,155</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeaseLiability_iI_zZwAlhsGEZwj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Present value of operating lease liability</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">147,701</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--OperatingLeaseLiabilityCurrent_iNI_di_z2VFP9dkux7b" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Less: current portion</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(97,185</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_405_eus-gaap--OperatingLeaseLiabilityNoncurrent_iI_z6skcjW23Np4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 2.5pt">Operating lease liability, net of current portion</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">50,516</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

72469

82387

154856

7155

147701

97185

50516

26542

6365

26182

6365

NOTE 9: SUBSEQUENT EVENTS The Company evaluated subsequent events from March 31, 2022, the date of these consolidated financial statements, through May 12, 2022, which represents the date the consolidated financial statements were issued, for events requiring recognition or disclosure in the condensed consolidated financial statements for the three-month period ended March 31, 2022. The Company concluded that no events have occurred that would require recognition or disclosure in the consolidated financial statements.

EXCEL 47 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 49 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 50 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.1 html 68 185 1 false 25 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://indaptusrx.com/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Condensed Consolidated Balance Sheets Sheet http://indaptusrx.com/role/BalanceSheets Condensed Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical) Sheet http://indaptusrx.com/role/BalanceSheetsParenthetical Condensed Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited) Sheet http://indaptusrx.com/role/StatementsOfOperations Condensed Consolidated Statements of Operations (Unaudited) Statements 4 false false R5.htm 00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Sheet http://indaptusrx.com/role/StatementsOfStockholdersEquityDeficit Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) Statements 5 false false R6.htm 00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://indaptusrx.com/role/StatementsOfCashFlows Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 00000007 - Disclosure - GENERAL Sheet http://indaptusrx.com/role/General GENERAL Notes 7 false false R8.htm 00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES Sheet http://indaptusrx.com/role/SignificantAccountingPolicies SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - MARKETABLE SECURITIES Sheet http://indaptusrx.com/role/MarketableSecurities MARKETABLE SECURITIES Notes 9 false false R10.htm 00000010 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS Sheet http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssets PREPAID EXPENSES AND OTHER CURRENT ASSETS Notes 10 false false R11.htm 00000011 - Disclosure - ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES Sheet http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilities ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES Notes 11 false false R12.htm 00000012 - Disclosure - STOCK-BASED COMPENSATION Sheet http://indaptusrx.com/role/Stock-basedCompensation STOCK-BASED COMPENSATION Notes 12 false false R13.htm 00000013 - Disclosure - CAPITALIZATION Sheet http://indaptusrx.com/role/Capitalization CAPITALIZATION Notes 13 false false R14.htm 00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://indaptusrx.com/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 14 false false R15.htm 00000015 - Disclosure - SUBSEQUENT EVENTS Sheet http://indaptusrx.com/role/SubsequentEvents SUBSEQUENT EVENTS Notes 15 false false R16.htm 00000016 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 16 false false R17.htm 00000017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://indaptusrx.com/role/SignificantAccountingPoliciesTables SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://indaptusrx.com/role/SignificantAccountingPolicies 17 false false R18.htm 00000018 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) Sheet http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssetsTables PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables) Tables http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssets 18 false false R19.htm 00000019 - Disclosure - ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Tables) Sheet http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilitiesTables ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Tables) Tables http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilities 19 false false R20.htm 00000020 - Disclosure - STOCK-BASED COMPENSATION (Tables) Sheet http://indaptusrx.com/role/Stock-basedCompensationTables STOCK-BASED COMPENSATION (Tables) Tables http://indaptusrx.com/role/Stock-basedCompensation 20 false false R21.htm 00000021 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables) Sheet http://indaptusrx.com/role/CommitmentsAndContingenciesTables COMMITMENTS AND CONTINGENCIES (Tables) Tables http://indaptusrx.com/role/CommitmentsAndContingencies 21 false false R22.htm 00000022 - Disclosure - GENERAL (Details Narrative) Sheet http://indaptusrx.com/role/GeneralDetailsNarrative GENERAL (Details Narrative) Details http://indaptusrx.com/role/General 22 false false R23.htm 00000023 - Disclosure - SCHEDULE OF ANTI-DILUTIVE SECURITIES (Details) Sheet http://indaptusrx.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails SCHEDULE OF ANTI-DILUTIVE SECURITIES (Details) Details 23 false false R24.htm 00000024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://indaptusrx.com/role/SignificantAccountingPoliciesTables 24 false false R25.htm 00000025 - Disclosure - MARKETABLE SECURITIES (Details Narrative) Sheet http://indaptusrx.com/role/MarketableSecuritiesDetailsNarrative MARKETABLE SECURITIES (Details Narrative) Details http://indaptusrx.com/role/MarketableSecurities 25 false false R26.htm 00000026 - Disclosure - SCHEDULE OF PREPAID EXPENSE AND OTHER CURRENT ASSETS (Details) Sheet http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails SCHEDULE OF PREPAID EXPENSE AND OTHER CURRENT ASSETS (Details) Details 26 false false R27.htm 00000027 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Details) Sheet http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails SCHEDULE OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Details) Details 27 false false R28.htm 00000028 - Disclosure - SCHEDULE OF SHARE BASED COMPENSATION (Details) Sheet http://indaptusrx.com/role/ScheduleOfShareBasedCompensationDetails SCHEDULE OF SHARE BASED COMPENSATION (Details) Details 28 false false R29.htm 00000029 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION EXPENSES (Details) Sheet http://indaptusrx.com/role/ScheduleOfStockBasedCompensationExpensesDetails SCHEDULE OF STOCK BASED COMPENSATION EXPENSES (Details) Details 29 false false R30.htm 00000030 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED (Details) Sheet http://indaptusrx.com/role/ScheduleOfWeightedAverageInputsUsedToMeasureValueOfOptionsGrantedDetails SCHEDULE OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED (Details) Details 30 false false R31.htm 00000031 - Disclosure - SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS (Details) Sheet http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS (Details) Details 31 false false R32.htm 00000032 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative) Sheet http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative STOCK-BASED COMPENSATION (Details Narrative) Details http://indaptusrx.com/role/Stock-basedCompensationTables 32 false false R33.htm 00000033 - Disclosure - CAPITALIZATION (Details Narrative) Sheet http://indaptusrx.com/role/CapitalizationDetailsNarrative CAPITALIZATION (Details Narrative) Details http://indaptusrx.com/role/Capitalization 33 false false R34.htm 00000034 - Disclosure - SUMMARY OF MINIMUM LEASE PAYMENTS (Details) Sheet http://indaptusrx.com/role/SummaryOfMinimumLeasePaymentsDetails SUMMARY OF MINIMUM LEASE PAYMENTS (Details) Details 34 false false R35.htm 00000035 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://indaptusrx.com/role/CommitmentsAndContingenciesTables 35 false false All Reports Book All Reports form10q.htm ex31-1.htm ex31-2.htm ex32-1.htm ex32-2.htm indp-20220331.xsd indp-20220331_cal.xml indp-20220331_def.xml indp-20220331_lab.xml indp-20220331_pre.xml http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 52 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10q.htm": { "axisCustom": 0, "axisStandard": 12, "contextCount": 68, "dts": { "calculationLink": { "local": [ "indp-20220331_cal.xml" ] }, "definitionLink": { "local": [ "indp-20220331_def.xml" ] }, "inline": { "local": [ "form10q.htm" ] }, "labelLink": { "local": [ "indp-20220331_lab.xml" ] }, "presentationLink": { "local": [ "indp-20220331_pre.xml" ] }, "schema": { "local": [ "indp-20220331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 306, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 39, "http://indaptusrx.com/20220331": 3, "http://xbrl.sec.gov/dei/2022": 6, "total": 48 }, "keyCustom": 21, "keyStandard": 164, "memberCustom": 11, "memberStandard": 13, "nsprefix": "INDP", "nsuri": "http://indaptusrx.com/20220331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "role": "http://indaptusrx.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "INDP:PrepaidExpenseAndOtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS", "role": "http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssets", "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "INDP:PrepaidExpenseAndOtherCurrentAssetsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES", "role": "http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilities", "shortName": "ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - STOCK-BASED COMPENSATION", "role": "http://indaptusrx.com/role/Stock-basedCompensation", "shortName": "STOCK-BASED COMPENSATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "INDP:CapitalizationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - CAPITALIZATION", "role": "http://indaptusrx.com/role/Capitalization", "shortName": "CAPITALIZATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "INDP:CapitalizationTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES", "role": "http://indaptusrx.com/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - SUBSEQUENT EVENTS", "role": "http://indaptusrx.com/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Policies)", "role": "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Tables)", "role": "http://indaptusrx.com/role/SignificantAccountingPoliciesTables", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "INDP:PrepaidExpenseAndOtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "INDP:ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)", "role": "http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssetsTables", "shortName": "PREPAID EXPENSES AND OTHER CURRENT ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "INDP:PrepaidExpenseAndOtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "INDP:ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Tables)", "role": "http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilitiesTables", "shortName": "ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Condensed Consolidated Balance Sheets", "role": "http://indaptusrx.com/role/BalanceSheets", "shortName": "Condensed Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "role": "http://indaptusrx.com/role/Stock-basedCompensationTables", "shortName": "STOCK-BASED COMPENSATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - COMMITMENTS AND CONTINGENCIES (Tables)", "role": "http://indaptusrx.com/role/CommitmentsAndContingenciesTables", "shortName": "COMMITMENTS AND CONTINGENCIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - GENERAL (Details Narrative)", "role": "http://indaptusrx.com/role/GeneralDetailsNarrative", "shortName": "GENERAL (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "us-gaap:NatureOfOperations", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2021-07-252021-07-26_custom_ShareholdersEquityPostReverseShareSplitMember", "decimals": null, "lang": "en-US", "name": "us-gaap:StockholdersEquityReverseStockSplit", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - SCHEDULE OF ANTI-DILUTIVE SECURITIES (Details)", "role": "http://indaptusrx.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails", "shortName": "SCHEDULE OF ANTI-DILUTIVE SECURITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_PropertyPlantAndEquipmentMember_custom_ComputersAndOtherOfficeEquipmentMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "role": "http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative", "shortName": "SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2021-01-012021-12-31_us-gaap_PropertyPlantAndEquipmentMember_custom_ComputersAndOtherOfficeEquipmentMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:MarketableSecuritiesCurrent", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - MARKETABLE SECURITIES (Details Narrative)", "role": "http://indaptusrx.com/role/MarketableSecuritiesDetailsNarrative", "shortName": "MARKETABLE SECURITIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:MarketableSecuritiesTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "lang": null, "name": "us-gaap:MarketableSecuritiesUnrealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "INDP:ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock", "INDP:PrepaidExpenseAndOtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - SCHEDULE OF PREPAID EXPENSE AND OTHER CURRENT ASSETS (Details)", "role": "http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails", "shortName": "SCHEDULE OF PREPAID EXPENSE AND OTHER CURRENT ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "INDP:ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock", "INDP:PrepaidExpenseAndOtherCurrentAssetsTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PrepaidInsurance", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - SCHEDULE OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Details)", "role": "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails", "shortName": "SCHEDULE OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:AccountsPayableCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - SCHEDULE OF SHARE BASED COMPENSATION (Details)", "role": "http://indaptusrx.com/role/ScheduleOfShareBasedCompensationDetails", "shortName": "SCHEDULE OF SHARE BASED COMPENSATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "AsOf2021-12-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - SCHEDULE OF STOCK BASED COMPENSATION EXPENSES (Details)", "role": "http://indaptusrx.com/role/ScheduleOfStockBasedCompensationExpensesDetails", "shortName": "SCHEDULE OF STOCK BASED COMPENSATION EXPENSES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-012022-03-31_us-gaap_ResearchAndDevelopmentExpenseMember", "decimals": "0", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)", "role": "http://indaptusrx.com/role/BalanceSheetsParenthetical", "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - SCHEDULE OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED (Details)", "role": "http://indaptusrx.com/role/ScheduleOfWeightedAverageInputsUsedToMeasureValueOfOptionsGrantedDetails", "shortName": "SCHEDULE OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharePrice", "reportCount": 1, "unique": true, "unitRef": "USDPShares", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS (Details)", "role": "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails", "shortName": "SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - STOCK-BASED COMPENSATION (Details Narrative)", "role": "http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative", "shortName": "STOCK-BASED COMPENSATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - CAPITALIZATION (Details Narrative)", "role": "http://indaptusrx.com/role/CapitalizationDetailsNarrative", "shortName": "CAPITALIZATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "span", "td", "tr", "table", "INDP:CapitalizationTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "AsOf2022-03-31_us-gaap_WarrantMember", "decimals": "INF", "lang": null, "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - SUMMARY OF MINIMUM LEASE PAYMENTS (Details)", "role": "http://indaptusrx.com/role/SummaryOfMinimumLeasePaymentsDetails", "shortName": "SUMMARY OF MINIMUM LEASE PAYMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "AsOf2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsForRent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "role": "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsForRent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Condensed Consolidated Statements of Operations (Unaudited)", "role": "http://indaptusrx.com/role/StatementsOfOperations", "shortName": "Condensed Consolidated Statements of Operations (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "AsOf2020-12-31_us-gaap_PreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)", "role": "http://indaptusrx.com/role/StatementsOfStockholdersEquityDeficit", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "AsOf2020-12-31_us-gaap_PreferredStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "role": "http://indaptusrx.com/role/StatementsOfCashFlows", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": "0", "lang": null, "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000007 - Disclosure - GENERAL", "role": "http://indaptusrx.com/role/General", "shortName": "GENERAL", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - SIGNIFICANT ACCOUNTING POLICIES", "role": "http://indaptusrx.com/role/SignificantAccountingPolicies", "shortName": "SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - MARKETABLE SECURITIES", "role": "http://indaptusrx.com/role/MarketableSecurities", "shortName": "MARKETABLE SECURITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10q.htm", "contextRef": "From2022-01-01to2022-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MarketableSecuritiesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 25, "tag": { "INDP_AccruedBoardFeesCurrent": { "auth_ref": [], "calculation": { "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails": { "order": 5.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued board fees current.", "label": "Accrued board fees" } } }, "localname": "AccruedBoardFeesCurrent", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "INDP_AccruedResearchAndDevelopmentCostsPolicy": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for accrued research and development costs.", "label": "Research and development expenses" } } }, "localname": "AccruedResearchAndDevelopmentCostsPolicy", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "INDP_AccruedResearchAndDevelopmentCurrent": { "auth_ref": [], "calculation": { "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails": { "order": 4.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to research and development expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued research and development" } } }, "localname": "AccruedResearchAndDevelopmentCurrent", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "INDP_CapitalizationTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capitalization [Text Block]", "label": "CAPITALIZATION" } } }, "localname": "CapitalizationTextBlock", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/Capitalization" ], "xbrltype": "textBlockItemType" }, "INDP_CashReceivedForInterestEarnedOnDeposits": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash Received For Interest Earned On Deposits.", "label": "Cash received for interest earned on deposits" } } }, "localname": "CashReceivedForInterestEarnedOnDeposits", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "INDP_ComputersAndOtherOfficeEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computers and Other Office Equipment [Member]", "label": "Computers and Other Office Equipment [Member]" } } }, "localname": "ComputersAndOtherOfficeEquipmentMember", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "INDP_DelawareFranchiseTaxesPayableCurrent": { "auth_ref": [], "calculation": { "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails": { "order": 6.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Delaware franchise taxes payable current.", "label": "Delaware franchise taxes payable" } } }, "localname": "DelawareFranchiseTaxesPayableCurrent", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "INDP_DisclosureCapitalizationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Capitalization" } } }, "localname": "DisclosureCapitalizationAbstract", "nsuri": "http://indaptusrx.com/20220331", "xbrltype": "stringItemType" }, "INDP_DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Prepaid Expenses And Other Current Assets", "verboseLabel": "Schedule Of Prepaid Expense And Other Current Assets" } } }, "localname": "DisclosurePrepaidExpensesAndOtherCurrentAssetsAbstract", "nsuri": "http://indaptusrx.com/20220331", "xbrltype": "stringItemType" }, "INDP_EmployeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Employee [Member]", "label": "Employee [Member]" } } }, "localname": "EmployeeMember", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "INDP_ExercisePriceOfWarrantIssuedToPlacementAgent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price of warrant issued to the placement agent.", "label": "Exercise price of warrant issued to the placement agent" } } }, "localname": "ExercisePriceOfWarrantIssuedToPlacementAgent", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/GeneralDetailsNarrative" ], "xbrltype": "perShareItemType" }, "INDP_ExercisePriceRangeOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range One [Member]", "label": "Exercise Price Range One [Member]" } } }, "localname": "ExercisePriceRangeOneMember", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails" ], "xbrltype": "domainItemType" }, "INDP_ExercisePriceRangeThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Three [Member]", "label": "Exercise Price Range Three [Member]" } } }, "localname": "ExercisePriceRangeThreeMember", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails" ], "xbrltype": "domainItemType" }, "INDP_ExercisePriceRangeTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise Price Range Two [Member]", "label": "Exercise Price Range Two [Member]" } } }, "localname": "ExercisePriceRangeTwoMember", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails" ], "xbrltype": "domainItemType" }, "INDP_FurnitureMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Furniture [Member]", "label": "Furniture [Member]" } } }, "localname": "FurnitureMember", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "INDP_IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet": { "auth_ref": [], "calculation": { "http://indaptusrx.com/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase Decrease In Operating Lease Right of use Asset And Liability Net.", "label": "Operating lease right-of-use asset and liability, net" } } }, "localname": "IncreaseDecreaseInOperatingLeaseRightOfUseAssetAndLiabilityNet", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "INDP_IndaptusMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indaptus [Member]", "label": "Indaptus [Member]" } } }, "localname": "IndaptusMember", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/GeneralDetailsNarrative" ], "xbrltype": "domainItemType" }, "INDP_IssuanceExpenses": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.", "label": "Issuance expenses" } } }, "localname": "IssuanceExpenses", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/GeneralDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "INDP_NumberOfWarrantsIssuedToPlacementAgent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants to purchase Indaptus' common stock issued to the placement agent.", "label": "Number of warrants issued to the placement agent" } } }, "localname": "NumberOfWarrantsIssuedToPlacementAgent", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/GeneralDetailsNarrative" ], "xbrltype": "sharesItemType" }, "INDP_PatentsPolicy": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for patent costs.", "label": "Patents" } } }, "localname": "PatentsPolicy", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "INDP_PlanTwoThousandTwentyOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2021 Plan [Member]", "label": "2021 Plan [Member]" } } }, "localname": "PlanTwoThousandTwentyOneMember", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "INDP_PrepaidExpenseAndOtherCurrentAssetsTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for prepaid expenses and other current assets.", "label": "PREPAID EXPENSES AND OTHER CURRENT ASSETS" } } }, "localname": "PrepaidExpenseAndOtherCurrentAssetsTextBlock", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssets" ], "xbrltype": "textBlockItemType" }, "INDP_PrepaidResearchAndDevelopment": { "auth_ref": [], "calculation": { "http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails": { "order": 2.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for Research and Development that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid research and development" } } }, "localname": "PrepaidResearchAndDevelopment", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "INDP_ProceedsFromIssuanceOfPreFundedWarrantsGross": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Total net proceeds from issuance of pre-funded warrants and warrants to purchase Indaptus common stock.", "label": "Total net proceeds from issuance of pre-funded warrants and warrants to purchase Indaptus common stock" } } }, "localname": "ProceedsFromIssuanceOfPreFundedWarrantsGross", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/GeneralDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "INDP_ProceedsFromSimpleAgreementsforFutrueEquity": { "auth_ref": [], "calculation": { "http://indaptusrx.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds From Simple Agreements for Futrue Equity.", "label": "Proceeds from SAFEs, net" } } }, "localname": "ProceedsFromSimpleAgreementsforFutrueEquity", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "INDP_PurchaseAgreementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase Agreements [Member]", "label": "Purchase Agreements [Member]" } } }, "localname": "PurchaseAgreementsMember", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/GeneralDetailsNarrative" ], "xbrltype": "domainItemType" }, "INDP_RateOfIncreaseInLeaseRent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Rate of increase in iease rent.", "label": "Rate of increase in lease rent" } } }, "localname": "RateOfIncreaseInLeaseRent", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "INDP_ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of Prepaid Expense and Other Assets [Table Text Block]", "label": "SCHEDULE OF PREPAID EXPENSE AND OTHER CURRENT ASSETS" } } }, "localname": "ScheduleOfPrepaidExpenseAndOtherAssetsTableTextBlock", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/PrepaidExpensesAndOtherCurrentAssetsTables" ], "xbrltype": "textBlockItemType" }, "INDP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedAndCancelledWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based Compensation Arrangement By Share based Payment Award Options Forfeited And Cancelled Weighted Average Remaining Contractual Term.", "label": "Forfeited and Cancelled, Weighted average remaining contractual life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsForfeitedAndCancelledWeightedAverageRemainingContractualTerm", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/ScheduleOfShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "INDP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based Compensation Arrangement By Share based Payment Award Options Granted WeightedAverage Remaining Contractual Term.", "label": "Granted, Weighted average remaining contractual life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/ScheduleOfShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "INDP_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share based Compensation Arrangement By Share based Payment Award Options Outstanding Weighted Average Remaining Contractual Term", "label": "Outstanding at beginning of the period, Weighted average remaining contractual life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/ScheduleOfShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "INDP_ShareholdersEquityPostReverseShareSplitMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shareholders Equity Post Reverse Share Split [Member]", "label": "Shareholders Equity Post Reverse Share Split [Member]" } } }, "localname": "ShareholdersEquityPostReverseShareSplitMember", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/GeneralDetailsNarrative" ], "xbrltype": "domainItemType" }, "INDP_TwoYearLeaseAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Year Lease Agreement [Member]", "label": "Two Year Lease Agreement [Member]" } } }, "localname": "TwoYearLeaseAgreementMember", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "INDP_WeightedAverageGrantDateFairValueOfStockOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Weighted average grant date fair value of options granted.", "label": "Weighted average grant date fair value of options granted" } } }, "localname": "WeightedAverageGrantDateFairValueOfStockOptions", "nsuri": "http://indaptusrx.com/20220331", "presentation": [ "http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "country_CA": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "CANADA" } } }, "localname": "CA", "nsuri": "http://xbrl.sec.gov/country/2022", "presentation": [ "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r303", "r305", "r306" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r304" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r292" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r307" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r295" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r298" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/GeneralDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r311" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r308" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r306" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r294" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r309" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/GeneralDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r305" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r299" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r300" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r293" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r297" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r296" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r301" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r302" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r310" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://indaptusrx.com/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ExecutiveOfficerMember": { "auth_ref": [ "r113" ], "lang": { "en-us": { "role": { "label": "Executive Officer [Member]" } } }, "localname": "ExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_SegmentGeographicalDomain": { "auth_ref": [ "r111", "r112", "r150", "r151", "r271", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290" ], "localname": "SegmentGeographicalDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_StatementGeographicalAxis": { "auth_ref": [ "r111", "r112", "r150", "r151", "r271", "r278", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]" } } }, "localname": "StatementGeographicalAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r113", "r246" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://indaptusrx.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities incurred to vendors for goods and services received, and accrued liabilities classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Accounts payable and other current liabilities", "totalLabel": "Total accounts payable and other current liabilities" } } }, "localname": "AccountsPayableAndOtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets", "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r25", "r249" ], "calculation": { "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedProfessionalFeesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails": { "order": 3.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued professional fees" } } }, "localname": "AccruedProfessionalFeesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r19", "r35", "r36", "r37", "r263", "r276", "r277" ], "calculation": { "http://indaptusrx.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r34", "r37", "r44", "r45", "r46", "r70", "r71", "r72", "r220", "r245", "r272", "r273" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r17", "r249" ], "calculation": { "http://indaptusrx.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r70", "r71", "r72", "r199", "r200", "r201", "r223" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r153", "r204", "r205" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r193" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Stock-based compensation expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Anti-dilutive securities" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AreaOfLand": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area of land held.", "label": "Area of land" } } }, "localname": "AreaOfLand", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "areaItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://indaptusrx.com/role/GeneralDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r11", "r68", "r103", "r105", "r109", "r117", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r217", "r221", "r231", "r247", "r249", "r254", "r262" ], "calculation": { "http://indaptusrx.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets [Default Label]", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r4", "r24", "r68", "r117", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r217", "r221", "r231", "r247", "r249" ], "calculation": { "http://indaptusrx.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroupCurrent": { "auth_ref": [ "r121", "r249" ], "calculation": { "http://indaptusrx.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets held-for-sale that are not part of a disposal group, expected to be sold within a year or the normal operating cycle, if longer.", "label": "Assets held for sale" } } }, "localname": "AssetsHeldForSaleNotPartOfDisposalGroupCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r68", "r117", "r135", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r217", "r221", "r231", "r247" ], "calculation": { "http://indaptusrx.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "Total non-current assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current assets:" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r2", "r9", "r62" ], "calculation": { "http://indaptusrx.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r55", "r62", "r65" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash and cash equivalents at end of period", "periodStartLabel": "Cash and cash equivalents at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r55", "r232" ], "calculation": { "http://indaptusrx.com/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "Net (decrease) increase in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r147" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Warrant is exercisable price" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/GeneralDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]" } } }, "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/GeneralDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r30", "r256", "r267" ], "calculation": { "http://indaptusrx.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingent liabilities (Note 8)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r127", "r128", "r129", "r134", "r279" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r70", "r71", "r223" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheetsParenthetical", "http://indaptusrx.com/role/CapitalizationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheetsParenthetical", "http://indaptusrx.com/role/CapitalizationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r15", "r146" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheetsParenthetical", "http://indaptusrx.com/role/CapitalizationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r15", "r249" ], "calculation": { "http://indaptusrx.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock: $0.01 par value, 200,000,000 shares authorized as of March 31, 2022 and December 31, 2021; 8,258,597 shares issued and outstanding as of March 31, 2022 and December 31, 2021" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r39", "r41", "r42", "r48", "r258", "r269" ], "calculation": { "http://indaptusrx.com/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r67", "r219" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Principles of consolidation" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": { "auth_ref": [ "r116" ], "calculation": { "http://indaptusrx.com/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Realized Gain", "negatedLabel": "Realized gain on assets held for sale" } } }, "localname": "DebtSecuritiesAvailableForSaleRealizedGain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r60", "r122" ], "calculation": { "http://indaptusrx.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r155", "r156", "r194", "r195", "r197", "r206" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "STOCK-BASED COMPENSATION" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/Stock-basedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r49", "r75", "r76", "r77", "r78", "r79", "r83", "r84", "r86", "r87", "r88", "r91", "r92", "r224", "r225", "r259", "r270" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net loss available to common stockholders per share of common stock, basic and diluted" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r89", "r90" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Loss per share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued employee costs" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]" } } }, "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfStockBasedCompensationExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r196" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Weighted-average period over which unrecognized compensation expense is expected to be recognized" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r196" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Compensation cost not yet recognized related to unvested stock options" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r0", "r44", "r45", "r46", "r70", "r71", "r72", "r74", "r80", "r82", "r93", "r118", "r146", "r148", "r199", "r200", "r201", "r214", "r215", "r223", "r233", "r234", "r235", "r236", "r237", "r238", "r245", "r272", "r273", "r274" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/CapitalizationDetailsNarrative", "http://indaptusrx.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r227" ], "lang": { "en-us": { "role": { "documentation": "Class of asset." } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r226", "r228" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r229", "r230" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair value measurements" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r52" ], "calculation": { "http://indaptusrx.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r50" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfStockBasedCompensationExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r125", "r126" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfStockBasedCompensationExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r126" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement." } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfStockBasedCompensationExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r43", "r208", "r209", "r210", "r211", "r212", "r213" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaid": { "auth_ref": [ "r56", "r64" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.", "label": "Cash paid for income taxes" } } }, "localname": "IncomeTaxesPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": { "auth_ref": [ "r59" ], "calculation": { "http://indaptusrx.com/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.", "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities", "verboseLabel": "Accounts payable and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDeferredLiabilities": { "auth_ref": [ "r59" ], "calculation": { "http://indaptusrx.com/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.", "label": "Deferred transaction costs" } } }, "localname": "IncreaseDecreaseInDeferredLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r59" ], "calculation": { "http://indaptusrx.com/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_LeaseAndRentalExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "Base rent" } } }, "localname": "LeaseAndRentalExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseDiscountRate": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "Discount rate used by lessee to determine present value of operating lease payments.", "label": "Lease liability discount rate" } } }, "localname": "LesseeOperatingLeaseDiscountRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "SUMMARY OF MINIMUM LEASE PAYMENTS" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/CommitmentsAndContingenciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r244" ], "calculation": { "http://indaptusrx.com/role/SummaryOfMinimumLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total minimum lease payments" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/SummaryOfMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": { "auth_ref": [ "r244" ], "calculation": { "http://indaptusrx.com/role/SummaryOfMinimumLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.", "label": "2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/SummaryOfMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r244" ], "calculation": { "http://indaptusrx.com/role/SummaryOfMinimumLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "2022" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/SummaryOfMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r244" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedLabel": "Less: amount representing interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/SummaryOfMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r27", "r68", "r106", "r117", "r135", "r136", "r137", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r218", "r221", "r222", "r231", "r247", "r248" ], "calculation": { "http://indaptusrx.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r22", "r68", "r117", "r231", "r249", "r255", "r265" ], "calculation": { "http://indaptusrx.com/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r5", "r29", "r68", "r117", "r135", "r136", "r137", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r218", "r221", "r222", "r231", "r247", "r248", "r249" ], "calculation": { "http://indaptusrx.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesNoncurrent": { "auth_ref": [ "r6", "r7", "r8", "r12", "r13", "r68", "r117", "r135", "r136", "r137", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r218", "r221", "r222", "r231", "r247", "r248" ], "calculation": { "http://indaptusrx.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer.", "label": "Liabilities, Noncurrent", "totalLabel": "Total non-current liabilities" } } }, "localname": "LiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current liabilities:" } } }, "localname": "LiabilitiesNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_MarketableSecuritiesCurrent": { "auth_ref": [], "calculation": { "http://indaptusrx.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in marketable security, classified as current.", "label": "Marketable securities" } } }, "localname": "MarketableSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets", "http://indaptusrx.com/role/MarketableSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_MarketableSecuritiesPolicy": { "auth_ref": [ "r260" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment classified as marketable security.", "label": "Marketable Securities, Policy [Policy Text Block]", "verboseLabel": "Marketable securities" } } }, "localname": "MarketableSecuritiesPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketableSecuritiesTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.", "label": "MARKETABLE SECURITIES" } } }, "localname": "MarketableSecuritiesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/MarketableSecurities" ], "xbrltype": "textBlockItemType" }, "us-gaap_MarketableSecuritiesUnrealizedGainLoss": { "auth_ref": [ "r51" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment in marketable security.", "label": "Unrealized losses on marketable securities" } } }, "localname": "MarketableSecuritiesUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/MarketableSecuritiesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r94", "r102" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "GENERAL" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/General" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r55" ], "calculation": { "http://indaptusrx.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r55" ], "calculation": { "http://indaptusrx.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r55", "r58", "r61" ], "calculation": { "http://indaptusrx.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r1", "r38", "r40", "r46", "r47", "r61", "r68", "r73", "r75", "r76", "r77", "r78", "r81", "r82", "r85", "r103", "r104", "r107", "r108", "r110", "r117", "r135", "r136", "r137", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r225", "r231", "r257", "r268" ], "calculation": { "http://indaptusrx.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://indaptusrx.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfCashFlows", "http://indaptusrx.com/role/StatementsOfOperations", "http://indaptusrx.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r53" ], "calculation": { "http://indaptusrx.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Other income, net" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://indaptusrx.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r103", "r104", "r107", "r108", "r110" ], "calculation": { "http://indaptusrx.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r240" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Present value of operating lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/SummaryOfMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r240" ], "calculation": { "http://indaptusrx.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating lease liability, current portion", "negatedLabel": "Less: current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets", "http://indaptusrx.com/role/SummaryOfMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r240" ], "calculation": { "http://indaptusrx.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liability, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets", "http://indaptusrx.com/role/SummaryOfMinimumLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r241", "r243" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating lease payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r239" ], "calculation": { "http://indaptusrx.com/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r28" ], "calculation": { "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails": { "order": 7.0, "parentTag": "us-gaap_AccountsPayableAndOtherAccruedLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other accrued expenses" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfAccountsPayableAndOtherCurrentLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r10" ], "calculation": { "http://indaptusrx.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax": { "auth_ref": [ "r32", "r33", "r35" ], "calculation": { "http://indaptusrx.com/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.", "label": "Unrealized loss on available-for-sale securities", "verboseLabel": "Other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfOperations", "http://indaptusrx.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherPrepaidExpenseCurrent": { "auth_ref": [ "r23", "r120" ], "calculation": { "http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails": { "order": 4.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Other prepaid expenses" } } }, "localname": "OtherPrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivables": { "auth_ref": [ "r16" ], "calculation": { "http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails": { "order": 3.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount due from parties in nontrade transactions, classified as other.", "label": "Other receivables" } } }, "localname": "OtherReceivables", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForRent": { "auth_ref": [ "r57" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash payments to lessor's for use of assets under operating leases.", "label": "Rental expense" } } }, "localname": "PaymentsForRent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireMarketableSecurities": { "auth_ref": [ "r115" ], "calculation": { "http://indaptusrx.com/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for purchase of marketable security.", "label": "Payments to Acquire Marketable Securities", "negatedLabel": "Purchase of marketable securities" } } }, "localname": "PaymentsToAcquireMarketableSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r156", "r157", "r158", "r161", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r171", "r172", "r173", "r174", "r175", "r176", "r178", "r179", "r181", "r182", "r186", "r187", "r188", "r189", "r190" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r156", "r157", "r158", "r161", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r171", "r172", "r173", "r174", "r175", "r176", "r178", "r179", "r181", "r182", "r186", "r187", "r188", "r189", "r190" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement." } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.", "label": "Preferred Stock [Member]" } } }, "localname": "PreferredStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r24" ], "calculation": { "http://indaptusrx.com/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 }, "http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets", "http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidInsurance": { "auth_ref": [ "r3", "r119", "r120" ], "calculation": { "http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails": { "order": 1.0, "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid insurance" } } }, "localname": "PrepaidInsurance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfPrepaidExpenseAndOtherCurrentAssetsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrivatePlacementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.", "label": "Private Placement [Member]" } } }, "localname": "PrivatePlacementMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/GeneralDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ProceedsFromSaleOfPropertyHeldForSale": { "auth_ref": [ "r54" ], "calculation": { "http://indaptusrx.com/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the sale of formerly productive land held for sale, anything permanently fixed to it, including buildings, structures on it, and so forth.", "label": "Proceeds received for assets held for sale" } } }, "localname": "ProceedsFromSaleOfPropertyHeldForSale", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductLiabilityContingencyLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Liability Contingency [Line Items]" } } }, "localname": "ProductLiabilityContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ProductLiabilityContingencyTable": { "auth_ref": [ "r130", "r131", "r132", "r133" ], "lang": { "en-us": { "role": { "documentation": "Information and financial data about the reasonably possible loss or the recognized and additional reasonably possible loss from product liability related to an individual product.", "label": "Product Liability Contingency [Table]" } } }, "localname": "ProductLiabilityContingencyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment [Member]" } } }, "localname": "PropertyPlantAndEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r124", "r249", "r261", "r266" ], "calculation": { "http://indaptusrx.com/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r124", "r280", "r281" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property and equipment" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r123" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Estimated useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r207", "r252", "r291" ], "calculation": { "http://indaptusrx.com/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfStockBasedCompensationExpensesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r18", "r148", "r249", "r264", "r275", "r277" ], "calculation": { "http://indaptusrx.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets", "http://indaptusrx.com/role/GeneralDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r0", "r70", "r71", "r72", "r74", "r80", "r82", "r118", "r199", "r200", "r201", "r214", "r215", "r223", "r272", "r274" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/GeneralDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.", "label": "SCHEDULE OF ACCOUNTS PAYABLE AND OTHER CURRENT LIABILITIES" } } }, "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/AccountsPayableAndOtherCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r89" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "SCHEDULE OF ANTI-DILUTIVE SECURITIES" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/SignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]" } } }, "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/GeneralDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "auth_ref": [ "r192", "r203" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfStockBasedCompensationExpensesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r124" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/SignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r170", "r177", "r180" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.", "label": "SCHEDULE OF STOCK BASED COMPENSATION EXPENSES" } } }, "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r152", "r154", "r156", "r157", "r158", "r161", "r163", "r164", "r165", "r166", "r167", "r168", "r169", "r171", "r172", "r173", "r174", "r175", "r176", "r178", "r179", "r181", "r182", "r186", "r187", "r188", "r189", "r190" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "Details comprising a table providing supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.", "label": "SCHEDULE OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS" } } }, "localname": "ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r160", "r177", "r180" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "SCHEDULE OF SHARE BASED COMPENSATION" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "SCHEDULE OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/Stock-basedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r59" ], "calculation": { "http://indaptusrx.com/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Total stock-based compensation expense", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfStockBasedCompensationExpensesDetails", "http://indaptusrx.com/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r171", "r172" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Warrant outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/CapitalizationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r171", "r172" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Weighted average exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/CapitalizationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": { "auth_ref": [ "r181" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Weighted average, remaining contractual life" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/CapitalizationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.", "label": "Exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfWeightedAverageInputsUsedToMeasureValueOfOptionsGrantedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r188" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Dividend yield" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfWeightedAverageInputsUsedToMeasureValueOfOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r187" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Volatility rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfWeightedAverageInputsUsedToMeasureValueOfOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r189" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Risk free rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfWeightedAverageInputsUsedToMeasureValueOfOptionsGrantedDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "Share based Compensation arrangement by share based payment award, number of shares available for grant" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "periodEndLabel": "Exercisable at end of period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r164" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Options exercisable price", "periodEndLabel": "Exercisable at end of period, Exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfShareBasedCompensationDetails", "http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period", "negatedLabel": "Forfeited and cancelled" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r165" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price of options that were either forfeited or expired.", "label": "Forfeited and cancelled, exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Granted", "verboseLabel": "Options granted to purchase of shares" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfShareBasedCompensationDetails", "http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r198" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "periodEndLabel": "Outstanding at end of period, intrinsic value", "periodStartLabel": "Outstanding at beginning of the period, Intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r161", "r163" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of period", "periodStartLabel": "Outstanding at beginning of the period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r161", "r163" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at end of period, Exercise price", "periodStartLabel": "Outstanding at beginning of the period, Exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": { "auth_ref": [ "r181" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value", "periodEndLabel": "Vested and expected to vest, intrinsic value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r181" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "periodEndLabel": "Vested and expected to vest" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r181" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Vested and expected to vest, Exercise price" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r166" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Granted, exercise price" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfShareBasedCompensationDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "auth_ref": [ "r159", "r184", "r185", "r186", "r187", "r190", "r202", "r206" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.", "label": "Share-Based Payment Arrangement [Policy Text Block]", "verboseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": { "auth_ref": [ "r183" ], "lang": { "en-us": { "role": { "documentation": "Information by range of option prices pertaining to options granted.", "label": "Exercise Price Range [Axis]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices." } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Exercise price range lower range limit" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions": { "auth_ref": [ "r162" ], "lang": { "en-us": { "role": { "documentation": "The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.", "label": "Outstanding options, number of outstanding options at the end of period" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": { "auth_ref": [ "r191" ], "lang": { "en-us": { "role": { "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.", "label": "Exercise price range upper range limit" } } }, "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfExercisePriceOfOutstandingStockOptionsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Stock Price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfWeightedAverageInputsUsedToMeasureValueOfOptionsGrantedDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r157" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Options expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/Stock-basedCompensationDetailsNarrative" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r186" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Expected term" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfWeightedAverageInputsUsedToMeasureValueOfOptionsGrantedDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r198" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "periodEndLabel": "Exercisable at end of period, intrinsic value" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfShareBasedCompensationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r198" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Exercisable at end of period, Weighted average remaining contractual life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r181" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Outstanding at end of period, Weighted average remaining contractual life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r181" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Vested and expected to vest, Weighted average remaining contractual life" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfShareBasedCompensationDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance, shares", "periodStartLabel": "Beginning balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r66", "r69" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/SignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r0", "r31", "r44", "r45", "r46", "r70", "r71", "r72", "r74", "r80", "r82", "r93", "r118", "r146", "r148", "r199", "r200", "r201", "r214", "r215", "r223", "r233", "r234", "r235", "r236", "r237", "r238", "r245", "r272", "r273", "r274" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/CapitalizationDetailsNarrative", "http://indaptusrx.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/CapitalizationDetailsNarrative", "http://indaptusrx.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r70", "r71", "r72", "r93", "r253" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/CapitalizationDetailsNarrative", "http://indaptusrx.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r14", "r15", "r146", "r148", "r167" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Exercised" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfShareBasedCompensationDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).", "label": "Equity Option [Member]" } } }, "localname": "StockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r15", "r20", "r21", "r68", "r114", "r117", "r231", "r249" ], "calculation": { "http://indaptusrx.com/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance, value", "periodStartLabel": "Beginning balance, value", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets", "http://indaptusrx.com/role/StatementsOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityReverseStockSplit": { "auth_ref": [ "r149" ], "lang": { "en-us": { "role": { "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.", "label": "Intec Israel, Reverse Share Split Conversion Ratio" } } }, "localname": "StockholdersEquityReverseStockSplit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/GeneralDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r250", "r251" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/GeneralDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SupplementalCashFlowElementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental cash flow disclosures" } } }, "localname": "SupplementalCashFlowElementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r216" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/CommitmentsAndContingenciesDetailsNarrative", "http://indaptusrx.com/role/GeneralDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r95", "r96", "r97", "r98", "r99", "r100", "r101" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/SignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/CapitalizationDetailsNarrative", "http://indaptusrx.com/role/ScheduleOfAnti-dilutiveSecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r83", "r88" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average number of shares used in calculating net loss per share, basic and diluted" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://indaptusrx.com/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592" }, "r102": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126982154&loc=d3e400-110220" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308" }, "r129": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(23))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751" }, "r134": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.C)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)-(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907" }, "r206": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19279-110258" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662" }, "r251": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(b)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "310", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Topic": "948", "URI": "https://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column B))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column C))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column D))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column E))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column F))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column G))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column H))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Column I))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756" }, "r292": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12" }, "r293": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r294": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r295": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23" }, "r296": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r297": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g" }, "r298": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d" }, "r299": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)(1)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r300": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r301": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d" }, "r302": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r303": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310" }, "r304": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a" }, "r305": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f" }, "r306": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f" }, "r307": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1" }, "r308": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405" }, "r309": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r310": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r311": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(24))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690" }, "r69": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(25))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 201.5-02(26))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592" } }, "version": "2.1" } ZIP 53 0001493152-22-012931-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-22-012931-xbrl.zip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end